BCL2 family of apoptosis-related genes: Functions and clinical implications in cancer

Critical Reviews in Clinical Laboratory Sciences

Volumn 43, Issue 1, 2006, Pages 1-67

  Thomadaki, Hellinida ^a   Scorilas, Andreas ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Apoptosis; BAK1; BAX; BBC3; BCL 2; BCL2 gene family; BCL2A1; BCL2L1; BCL2L11; BCL2L12; BCL2L13; BCL2L14; BCL2L2; BCLAF1; BID; BIK; BLK; BMF; BNIP; BNIP1; BNIP2; BNIP3; BOK; BOO DIVA; Cancer; Cancer prognosis; Cancer treatment; ceBNIP3; HRK; MCL1; NIX; PMAIP1; Tumour biomarkers

Indexed keywords

BIOLOGICAL MARKER; MICROTUBULE ASSOCIATED PROTEIN 1; PROTEIN BAX; PROTEIN BCL 2;

APOPTOSIS; BCL2 GENE; BCL2A1 GENE; BCL2L1 GENE; BCL2L10 GENE; BCL2L12 GENE; BCL2L13 GENE; BCL2L14 GENE; BCL2L2 GENE; BCLAF1 GENE; BFK GENE; CANCER GROWTH; CANCER RELAPSE; CARCINOGENESIS; CLONE; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; GENE EXPRESSION; GENE FUNCTION; HOMEOSTASIS; HUMAN; MAP 1 GENE; MULTIGENE FAMILY; NONHUMAN; ONCOGENE; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REGULATORY MECHANISM; REVIEW;

ANIMALS; GENE TARGETING; GENES, BCL-2; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR MARKERS, BIOLOGICAL;

EID: 33644928489     PISSN: 10408363     EISSN: None     Source Type: Journal    
DOI: 10.1080/10408360500295626     Document Type: Review

References (484)

1. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239-257.
2. Saikumar P, Dong Z, Mikhailov V, Denton M, Weinberg JM, Venkatachalam MA. Apoptosis: definition, mechanisms, and relevance to disease. Am J Med 1999; 107: 489-506.
3. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456-1462.
4. Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 1998; 188: 2199-2204.
5. Hueber AO, Evan GI. Traps to catch unwary oncogenes. Trends Genet 1998; 14: 364-367.
6. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 38-47.
7. Winoto A. Cell death in the regulation of immune responses. Curr Opin Immunol 1997; 9: 365-370.
8. Yin XM, Oltvai ZN, Korsmeyer SJ. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 1994; 369: 321-323.
9. Cheng EH, Levine B, Boise LH, Thompson CB, Hardwick JM. Bax-independent inhibition of apoptosis by Bcl-XL. Nature 1996; 379: 554-556.
10. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998; 281: 1322-1326.
11. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999; 13: 1899-1911.
12. Oltvai ZN, Korsmeyer SJ. Checkpoints of dueling dimers foil death wishes. Cell 1994; 79: 189-192.
13. Nguyen M, Millar DG, Yong VW, Korsmeyer SJ, Shore GC. Targeting of Bcl-2 to the mitochondrial outer membrane by a COOH-terminal signal anchor sequence. J Biol Chem 1993; 268: 25265-25268.
14. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334-336.
15. Krajewski S, Tanaka S, Takayama S, Schibler MJ, Fenton W, Reed JC. Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res 1993; 53: 4701-4714.
16. De Jong D, Prins FA, Mason DY, Reed JC, van Ommen GB, Kluin PM. Subcellular localization of the bcl-2 protein in malignant and normal lymphoid cells. Cancer Res 1994; 54: 256-260.
17. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 1997; 275: 1132-1136.
18. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP, Wang X. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997; 275: 1129-1132.
19. Ottilie S, Diaz JL, Home W, Chang J, Wang Y, Wilson G, Chang S, Weeks S, Fritz LC, Oltersdorf T. Dimerization properties of human BAD. Identification of a BH-3 domain and analysis of its binding to mutant BCL-2 and BCL-XL proteins. J Biol Chem 1997; 272: 30866-30872.
20. Gross A, Yin XM, Wang K, Wei MC, Jockel J, Milliman C, Erdjument-Bromage H, Tempst P, Korsmeyer SJ. Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J Biol Chem 1999; 274: 1156-1163.
21. McDonnell JM, Fushman D, Milliman CL, Korsmeyer SJ, Cowburn D. Solution structure of the proapoptotic molecule BID: a structural basis for apoptotic agonists and antagonists. Cell 1999; 96: 625-634.
22. Muchmore SW, Sattler M, Liang H, Meadows RP, Harlan JE, Yoon HS, Nettesheim D, Chang BS, Thompson CB, Wong SL, Ng SL, Fesik SW. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 1996; 381: 335-341.
23. Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 1984; 226: 1097-1099.
24. Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985; 228: 1440-1443.
25. Bakhshi A, Jensen JP, Goldman P, Wright JJ, McBride OW, Epstein AL, Korsmeyer SJ. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 1985; 41: 899-906.
26. Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 1986; 83: 5214-5218.
27. Cleary ML, Smith SD, Sklar J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell 1986; 47: 19-28.
28. Katsumata M, Siegel RM, Louie DC, Miyashita T, Tsujimoto Y, Nowell PC, Greene MI, Reed JC. Differential effects of Bcl-2 on T and B cells in transgenic mice. Proc Natl Acad Sci USA 1992; 89: 11376-11380.
29. Haldar S, Jena N, DuBois GC, Takayama S, Reed JC, Fu SS, Croce CM. Purification and characterization of the bcl-2 protein. Arch Biochem Biophys 1994; 315: 483-488.
30. Lithgow T, van Driel R, Bertram JF, Strasser A. The protein product of the oncogene bcl-2 is a component of the nuclear envelope, the endoplasmic reticulum, and the outer mitochondrial membrane. Cell Growth Differ 1994; 5: 411-417.
31. Riparbelli MG, Callaini G, Tripodi SA, Cintorino M, Tosi P, Dallai R. Localization of the Bcl-2 protein to the outer mitochondrial membrane by electron microscopy. Exp Cell Res 1995; 221: 363-369.
32. Kanada M, Aime-Sempe C, Sato T, Reed JC. Structure-function analysis of Bcl-2 protein. Identification of conserved domains important for homodimerization with Bcl-2 and heterodimerization with Bax. J Biol Chem 1995; 270: 11962-11969.
33. Kirkin V, Joos S, Zornig M. The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta 2004; 1644: B229-B249.
34. Nunez G, Hockenbery D, McDonnell TJ, Sorensen CM, Korsmeyer SJ. Bcl-2 maintains B cell memory. Nature 1991; 353: 71-73.
35. Strasser A, Whittingham S, Vaux DL, Bath ML, Adams JM, Cory S, Harris AW. Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci USA 1991; 88: 8661-8665.
36. Merry DE, Veis DJ, Hickey WF, Korsmeyer SJ. bcl-2 protein expression is widespread in the developing nervous system and retained in the adult PNS. Development 1994; 120: 301-311.
37. Linette GP, Grusby MJ, Hedrick SM, Hansen TH, Glimcher LH, Korsmeyer SJ. Bcl-2 is upregulated at the CD4+ CD8+ stage during positive selection and promotes thymocyte differentiation at several control points. Immunity 1994; 1: 197-205.
38. LeBrun DP, Warnke RA, Cleary ML. Expression of bcl-2 in fetal tissues suggests a role in morphogenesis. Am J Pathol 1993; 142: 743-753.
39. Novack DV, Korsmeyer SJ. Bcl-2 protein expression during murine development. Am J Pathol 1994; 145: 61-73.
40. Michaelidis TM, Sendtner M, Cooper JD, Airaksinen MS, Holtmann B, Meyer M, Thoenen H. Inactivation of bcl-2 results in progressive degeneration of motoneurons, sympathetic and sensory neurons during early postnatal development. Neuron 1996; 17: 75-89.
41. Murasawa M, Okada S, Obata S, Hatano M, Moriya H, Tokuhisa T. GL7 defines the cycling stage of pre-B cells in murine bone marrow. Eur J Immunol 2002; 32: 291-298.
42. Schorr K, Li M, Krajewski S, Reed JC, Furth PA. Bcl-2 gene family and related proteins in mammary gland involution and breast cancer. J Mammary Gland Biol Neoplasia 1999; 4: 153-164.
43. Srinivas G, Kusumakumary P, Nair MK, Panicker KR, Pillai MR. Bcl-2 protein and apoptosis in pediatric acute lymphoblastic leukaemia. Int J Mol Med 1998; 1: 755-759.
44. Greenlund LJ, Korsmeyer SJ, Johnson EM Jr. Role of BCL-2 in the survival and function of developing and mature sympathetic neurons. Neuron 1995; 15: 649-661.
45. Memon SA, Moreno MB, Petrak D, Zacharchuk CM. Bcl-2 blocks glucocorticoid- but not Fas- or activation-induced apoptosis in a T cell hybridoma. J Immunol 1995; 155: 4644-4652.
46. Kobzdej M, MatuszykJ, Ziolo E, Strzadala L. Changes in glucocorticoid-induced apoptosis and in expression of Bcl-2 protein during long-term culture of thymic lymphoma. Arch Immunol Ther Exp 2000; 48: 43-46.
47. Von Freeden-Jeffry U, Solvason N, Howard M, Murray R. The earliest T lineage-committed cells depend on IL-7 for Bcl-2 expression and normal cell cycle progression. Immunity 1997; 7: 147-154.
48. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B, Reed JC. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9: 1799-1805.
49. Watabe M, Kawazoe N, Masuda Y, Nakajo S, Nakaya K. Bcl-2 protein inhibits bufalin-induced apoptosis through inhibition of mitogen-activated protein kinase activation in human leukemia U937 cells. Cancer Res 1997; 57: 3097-3100.
50. Harada K, Ishibashi S, Miyashita T, Osuga J, Yagyu H, Ohashi K, Yazaki Y, Yamada N. Bcl-2 protein inhibits oxysterol-induced apoptosis through suppressing CPP32-mediated pathway. FEBS Lett 1997; 411: 63-66.
51. Haldar S, Jena N, Croce CM. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 1995; 92: 4507-4511.
52. Wang HG, Miyashita T, Takayama S, Sato T, Torigoe T, Krajewski S, Tanaka S, Hovey L 3rd, Troppmair J, Rapp UR, et al. Apoptosis regulation by interaction of Bcl-2 protein and Raf-1 kinase. Oncogene 1994; 9: 2751-2756.
53. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 1997; 90: 405-413.
54. Hu Y, Benedict MA, Wu D, Inohara N, Nunez G. Bcl-XL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. Proc Natl Acad Sci USA 1998; 95: 4386-4391.
55. Pan G, O'Rourke K, Dixit VM. Caspase-9, Bcl-XL, and Apaf-1 form a ternary complex. J Biol Chem 1998; 273: 5841-5845.
56. Cosulich SC, Savory PJ, Clarke PR. Bcl-2 regulates amplification of caspase activation by cytochrome c. Curr Biol 1999; 9: 147-150.
57. Antonsson B, Conti F, Ciavatta A, Montessuit S, Lewis S, Martinou I, Bernasconi L, Bernard A, Mermod JJ, Mazzei G, Maundrell K, Gambale F, Sadoul R, Martinou JC. Inhibition of Bax channel-forming activity by Bcl-2. Science 1997; 277: 370-372.
58. Schendel SL, Xie Z, Montal MO, Matsuyama S, Montal M, Reed JC. Channel formation by anti-apoptotic protein Bcl-2. Proc Natl Acad Sci USA 1997; 94: 5113-5118.
59. Schlesinger PH, Gross A, Yin XM, Yamamoto K, Saito M, Waksman G, Korsmeyer SJ. Comparison of the ion channel characteristics of proapoptotic BAX and antiapoptotic BCL-2. Proc Natl Acad Sci USA 1997; 94: 11357-11362.
60. Cory S, Adams JM. The Bc12 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002; 2: 647-656.
61. Grillot DA, Gonzalez-Garcia M, Ekhterae D, Duan L, Inohara N, Ohta S, Seldin MF, Nunez G. Genomic organization, promoter region analysis, and chromosome localization of the mouse bcl-x gene. J Immunol 1997; 158: 4750-4757.
62. Shimizu S, Narita M, Tsujimoto Y. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 1999; 399: 483-487.
63. Von Ahsen O, Renken C, Perkins G, Kluck RM, Bossy-Wetzel E, Newmeyer DD. Preservation of mitochondrial structure and function after Bid- or Bax-mediated cytochrome c release. J Cell Biol 2000; 150: 1027-1036.
64. Gonzalez-Garcia M, Perez-Ballestero R, Ding L, Duan L, Boise LH, Thompson CB, Nunez G. bcl-XL is the major bcl-x mRNA form expressed during murine development and its product localises to mitochondria. Development 1994; 120: 3033-3042.
65. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G, Thompson CB. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74: 597-608.
66. Krajewski S, Krajewska M, Shabaik A, Miyashita T, Wang HG, Reed JC. Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am J Pathol 1994; 145: 1323-1336.
67. Yang XF, Weber GF, Cantor H. A novel Bcl-x isoform connected to the T cell receptor regulates apoptosis in T cells. Immunity 1997; 7: 629-639.
68. Schorr K, Li M, Krajewski S, Reed JC, Furth PA. Bcl-2 gene family. J Mammary Gland Biol Neoplasia 1999; 4: 153-164.
69. Hsu YT, Wolter KG, Youle RJ. Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis. Proc Natl Acad Sci USA 1997; 94: 3668-3672.
70. Gross A, Jockel J, Wei MC, Korsmeyer SJ. Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J 1998; 17: 3878-3885.
71. Chou JJ, Li H, Salvesen GS, Yuan J, Wagner G. Solution structure of BID, an intracellular amplifier of apoptotic signalling. Cell 1999; 96: 615-624.
72. Minn AJ, Velez P, Schendel SL, Liang H, Muchmore SW, Fesik SW, Fill M, Thompson CB. Bcl-x(L) forms an ion channel in synthetic lipid membranes. Nature 1997; 385: 353-357.
73. Inohara N, Gourley TS, Carrio R, Muniz M, Merino J, Garcia I, Koseki T, Hu Y, Chen S, Nunez G. Diva, a Bcl-2 homologue that binds directly to Apaf-1 and induces BH3-independent cell death. J Biol Chem 1998; 273: 32479-32486.
74. Song Q, Kuang Y, Dixit VM, Vincenz C. Boo, a novel negative regulator of cell death, interacts with Apaf-1. EMBO J 1999; 18: 167-178.
75. Van Houten N, Blake SF, Li EJ, Hallam TA, Chilton DG, Gourley WK, Boise LH, Thompson CB, Thompson EB. Elevated expression of Bcl-2 and Bcl-x by intestinal intraepithelial lymphocytes: resistance to apoptosis by glucocorticoids and irradiation. Int Immunol 1997; 9: 945-953.
76. Leverrier Y, Thomas J, Mathieu AL, Low W, Blanquier B, Marvel J. Role of PI3-kinase in Bcl-X induction and apoptosis inhibition mediated by IL-3 or IGF-1 in Baf-3 cells. Cell Death Differ 1999; 6: 290-296.
77. Rong P, Bennie AM, Epa WR, Barrett GL. Nerve growth factor determines survival and death of PC12 cells by regulation of the bcl-x, bax, and caspase-3 genes. J Neurochem 1999; 72: 2294-2300.
78. Wang Z, Karras JG, Howard RG, Rothstein TL. Induction of bcl-x by CD40 engagement rescues sIg-induced apoptosis in murine B cells. J Immunol 1995; 155: 3722-3725.
79. Boise LH, Minn AJ, Noel PJ, June CH, Accavitti MA, Lindsten T, Thompson CB. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity 1995; 3: 87-98.
80. Kozopas KM, Yang T, Buchan HL, Zhou P, Craig RW. MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci USA 1993; 90: 3516-3520.
81. Bae J, Leo CP, Hsu SY, Hsueh AJ. MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain. J Biol Chem 2000; 275: 25255-25261.
82. Rogers S, Wells R, Rechsteiner M. Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis Science 1986; 234: 364-368.
83. Akgul C, Turner PC, White MR, Edwards SW. Functional analysis of the human MCL-1 gene. Cell Mol Life Sci 2000; 57: 684-691.
84. Yang T, Buchan HL, Townsend KJ, Craig RW. MCL-1, a member of the BLC-2 family, is induced rapidly in response to signals for cell differentiation or death, but not to signals for cell proliferation. J Cell Physiol 1996; 166: 523-536.
85. Townsend KJ, Trusty JL, Traupman MA, Eastman A, Craig RW. Expression of the antiapoptotic MCL1 gene product is regulated by a mitogen activated protein kinase-mediated pathway triggered through microtubule disruption and protein kinase C. Oncogene 1998; 17: 1223-1234.
86. Leuenroth SJ, Grutkoski PS, Ayala A, Simms HH. Suppression of PMN apoptosis by hypoxia is dependent on Mcl-1 and MAPK activity. Surgery 2000; 128: 171-177.
87. Boucher MJ, Morisset J, Vachon PH, Reed JC, Laine J, Rivard N. MEK/ERK signalling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J Cell Biochem 2000; 79: 355-369.
88. Leu CM, Chang C, Hu C. Epidermal growth factor (EGF) suppresses staurosporine-induced apoptosis by inducing mcl-1 via the mitogen-activated protein kinase pathway. Oncogene 2000; 19: 1665-1675.
89. Wang JM, Chao JR, Chen W, Kuo ML, Yen JJ, Yang-Yen HF. The antiapoptotic gene mcl-1 is upregulated by the phosphatidylinositol 3-kinase/Akt signalling pathway through a transcription factor complex containing CREB. Mol Cell Biol 1999; 19: 6195-6206.
90. Puthier D, Bataille R, Amiot M. IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur J Immunol 1999; 29: 3945-3950.
91. Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, Li Y, Wang JM, Yang-Yen HF, Karras J, Jove R, Loughran TP Jr., Inhibition of STAT3 signalling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression J Clin Invest 2001; 107: 351-362.
92. Epling-Burnette PK, Zhong B, Bai F, Jiang K, Bailey RD, Garcia R, Jove R, Djeu JY, Loughran TP Jr, Wei S. Cooperative regulation of Mcl-1 by Janus kinase/stat and phosphatidylinositol 3-kinase contribute to granulocyte- macrophage colony-stimulating factor-delayed apoptosis in human neutrophils. J Immunol 2001; 166: 7486-7495.
93. Liu H, Ma Y, Cole SM, Zander C, Chen KH, KarrasJ, Pope RM. Serine phosphorylation of STAT3 is essential for Mcl-1 expression and macrophage survival. Blood 2003; 102: 344-352.
94. Bingle CD, Craig RW, Swales BM, Singleton V, Zhou P, Whyte MK. Exon skipping in Mcl-1 results in a bcl-2 homology domain 3 only gene product that promotes cell death. J Biol Chem 2000; 275: 22136-22146.
95. Haldar S, Jena N, Croce CM. Antiapoptosis potential of bcl-2 oncogene by dephosphorylation. Biochem Cell Biol 1994; 72: 455-462.
96. Haldar S, Chintapalli J, Croce CM. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 1996; 56: 1253-1255.
97. Ito T, Deng X, Carr B, May WS. Bcl-2 phosphorylation required for anti-apoptosis function. J Biol Chem 1997; 272: 11671-11673.
98. Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997; 57: 229-233.
99. Haldar S, Basu A, Croce CM. Serine-70 is one of the critical sites for drug-induced Bcl2 phosphorylation in cancer cells. Cancer Res 1998; 58: 1609-1615.
100. Deng X, Ito T, Carr B, Mumby M, May WS Jr. Reversible phosphorylation of Bcl2 following interleukin 3 or bryostatin 1 is mediated by direct interaction with protein phosphatase 2A. J Biol Chem 1998; 273: 34157-34163.
101. Domina AM, Smith JH, Craig RW. Myeloid cell leukemia 1 is phosphorylated through two distinct pathways, one associated with extracellular signal-regulated kinase activation and the other with G2/M accumulation or protein phosphatase 1/2A inhibition. J Biol Chem 2000; 275: 21688-21694.
102. Krajewski S, Bodrug S, Krajewska M, Shabaik A, Gascoyne R, Berean K, Reed JC. Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo. Am J Pathol 1995; 146: 1309-1319.
103. Craig RW. MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia 2002; 16: 444-454.
104. Yang T, Kozopas KM, Craig RW. The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2. J Cell Biol 1995; 128: 1173-1184.
105. Zhou P, Qian L, Bieszczad CK, Noelle R, Binder M, Levy NB, Craig RW. Mcl-1 in transgenic mice promotes survival in a spectrum of hematopoietic cell types and immortalization in the myeloid lineage. Blood 1998; 92: 3226-3239.
106. Sordet O, Bettaieb A, Bruey JM, Eymin B, Droin N, Ivarsson M, Garrido C, Solary E. Selective inhibition of apoptosis by TPA-induced differentiation of U937 leukemic cells. Cell Death Differ 1999; 6: 351-361.
107. Lomo J, Smeland EB, Krajewski S, Reed JC, Blomhoff HK. Expression of the Bcl-2 homologue Mcl-1 correlates with survival of peripheral blood B lymphocytes. Cancer Res 1996; 56: 40-43.
108. Lomo J, Blomhoff HK, Jacobsen SE, Krajewski S, Reed JC, Smeland EB. Interleukin-13 in combination with CD40 ligand potently inhibits apoptosis in human B lymphocytes: upregulation of Bcl-xL and Mcl-1. Blood 1997; 89: 4415-4424.
109. Puthier D, Derenne S, Barille S, Moreau P, HarousseauJL, Bataille R, Amiot M. Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells. Br J Haematol 1999; 107: 392-395.
110. Puthier D, Thabard W, Rapp M, Etrillard M, HarousseauJ, Bataille R, Amiot M. Interferon alpha extends the survival of human myeloma cells through an upregulation of the Mcl-1 anti-apoptotic molecule. Br J Haematol 2001; 112: 358-363.
111. Chao JR, Wang JM, Lee SF, Peng HW, Lin YH, Chou CH, LiJC, Huang HM, Chou CK, Kuo ML, Yen JJ, Yang-Yen HF. mcl-1 is an immediate-early gene activated by the granulocyte-macrophage colony-stimulating factor (GM-CSF) signalling pathway and is one component of the GM-CSF viability response. Mol Cell Biol 1998; 18: 4883-4898.
112. Moulding DA, Quayle JA, Hart CA, Edwards SW. Mcl-1 expression in human neutrophils: regulation by cytokines and correlation with cell survival. Blood 1998; 92: 2495-2502.
113. Gibson L, Holmgreen SP, Huang DC, Bernard O, Copeland NG, Jenkins NA, Sutherland GR, Baker E, Adams JM, Cory S. bcl-w, a novel member of the bcl-2 family, promotes cell survival. Oncogene 1996; 13: 665-675.
114. Holmgreen SP, Huang DC, Adams JM, Cory S. Survival activity of Bcl-2 homologs Bcl-w and A1 only partially correlates with their ability to bind pro-apoptotic family members. Cell Death Differ 1999; 6: 525-532.
115. Hamner S, Skoglosa Y, Lindholm D. Differential expression of bcl-w and bcl-x messenger RNA in the developing and adult rat nervous system. Neuroscience 1999; 91: 673-684.
116. Print CG, Loveland KL, Gibson L, Meehan T, Stylianou A, Wreford N, de Kretser D, Metcalf D, Kontgen F, Adams JM, Cory S. Apoptosis regulator bcl-w is essential for spermatogenesis but appears otherwise redundant. Proc Natl Acad. Sci USA 1998; 95: 12424-12431.
117. Ross AJ, Waymire KG, Moss JE, Parlow AF, Skinner MK, Russell LD, MacGregor GR. Testicular degeneration in Bclw-deficient mice. Nat Genet 1998; 18: 251-256.
118. O'Reilly LA, Print C, Hausmann G, Moriishi K, Cory S, Huang DC, Strasser A. Tissue expression and subcellular localization of the pro-survival molecule Bcl-w. Cell Death Differ 2001; 8: 486-494.
119. Hinds MG, Lackmann M, Skea GL, Harrison PJ, Huang DC, Day CL. The structure of Bcl-w reveals a role for the C-terminal residues in modulating biological activity. EMBO J 2003; 22: 1497-1507.
120. Wilson-Annan J, O'Reilly LA, Crawford SA, Hausmann G, Beaumont JG, Parma LP, Chen L, Lackmann M, Lithgow T, Hinds MG, Day CL, Adams JM, Huang DC. Proapoptotic BH3-only proteins trigger membrane integration of prosurvival Bcl-w and neutralize its activity. J Cell Biol 2003; 162: 877-887.
121. Kaufmann T, Schinzel A, Borner C. Bcl-w(edding) with mitochondria. Trends Cell Biol 2004; 14: 8-12.
122. Yan W, Samson M, Jegou B, Toppari J. Bcl-w forms complexes with Bax and Bak, and elevated ratios of Bax/Bcl-w and Bak/Bcl-w correspond to spermatogonial and spermatocyte apoptosis in the testis. Mol Endocrinol 2000; 14: 682-699.
123. Kitamura S, Kondo S, Shinomura Y, Kanayama S, Miyazaki Y, Kiyohara T, Hiraoka S, Matsuzawa Y. Met/HGF receptor modulates bcl-w expression and inhibits apoptosis in human colorectal cancers. Br J Cancer 2000; 83: 668-673.
124. Yang L, Zhang B, Toku K, Maeda N, Sakanaka M, Tanaka J. Improvement of the viability of cultured rat neurons by the non-essential amino acids L-serine and glycine that upregulates expression of the anti-apoptotic gene product Bcl-w. Neurosci Lett 2000; 295: 97-100.
125. Yan C, Chen J, Chen D, Minami M, Pei W, Yin XM, Simon RP. Over-expression of the cell death suppressor Bcl-w in ischemic brain: implications for a neuroprotective role via the mitochondrial pathway. J Cereb Blood Flow Metab 2000; 20: 620-630.
126. Lee R, Chen J, Matthews CP, McDougall JK, Neiman PE. Characterization of NR13-related human cell death regulator, Boo/Diva, in normal and cancer tissues. Biochim Biophys Acta 2001; 1520: 187-194.
127. Karsan A, Yee E, Harlan JM. Endothelial cell death induced by tumor necrosis factor-alpha is inhibited by the Bcl-2 family member, A1. J Biol Chem 1996; 271: 27201-27204.
128. Kenny JJ, Knobloch TJ, Augustus M, Carter KC, Rosen CA, Lang JC. GRS, a novel member of the Bcl-2 gene family, is highly expressed in multiple cancer cell lines and in normal leukocytes. Oncogene 1997; 14: 997-1001.
129. Karsan A, Yee E, Kaushansky K, Harlan JM. Cloning of human Bcl-2 homologue: inflammatory cytokines induce human A1 in cultured endothelial cells. Blood 1996; 87: 3089-3096.
130. D'Sa-Eipper C, Chinnadurai G. Functional dissection of Bfl-1, a Bcl-2 homolog: anti-apoptosis, oncogene-cooperation and cell proliferation activities. Oncogene 1998; 16: 3105-3114.
131. Choi SS, Park IC, Yun JW, Sung YC, Hong SI, Shin HS. A novel Bcl-2 related gene, Bfl-1, is overexpressed in stomach cancer and preferentially expressed in bone marrow. Oncogene 1995; 11: 1693-1698.
132. Hatakeyama S, Hamasaki A, Negishi I, Loh DY, Sendo F, Nakayama K, Nakayama K. Multiple gene duplication and expression of mouse bcl-2-related genes, Al. Int Immunol 1998; 10: 631-637.
133. Ko JK, Lee MJ, Cho SH, Cho JA, Lee BY, Koh JS, Lee SS, Shim YH, Kim CW. Bfl-1S, a novel alternative splice variant of Bfl-1, localises in the nucleus via its C-terminus and prevents cell death. Oncogene 2003; 22: 2457-2465.
134. Pang XP, Hershman JM, Karsan A. TNF-alpha induction of A1 expression in human cancer cells. Oncol Res 1997; 9: 623-627.
135. Chuang PI, Yee E, Karsan A, Winn RK, Harlan JM. A1 is a constitutive and inducible Bcl-2 homologue in mature human neutrophils. Biochem Biophys Res Commun 1998; 249: 361-365.
136. Kremer L, Estaquier J, Brandt E, Ameisen JC, Locht C. Mycobacterium bovis Bacillus Calmette Guerin infection prevents apoptosis of resting human monocytes. Eur J Immunol 1997; 27: 2450-2456.
137. Orlofsky A, Somogyi RD, Weiss LM, Prystowsky MB. The murine antiapoptotic protein A1 is induced in inflammatory macrophages and constitutively expressed in neutrophils. J Immunol 1999; 163: 412-419.
138. Gross A, Terraza A, Ouahrani-Bettache S, Liautard JP, Dornand J. In vitro Brucella suis infection prevents the programmed cell death of human monocytic cells. Infect Immun 2000; 68: 342-351.
139. Gerber HP, Dixit V, Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 1998; 273: 13313-13316.
140. Feldman GM, Rosenthal LA, Liu X, Hayes MP, Wynshaw-Boris A, Leonard WJ, Hennighausen L, Finbloom DS. STAT5A-deficient mice demonstrate a defect in granulocyte-macrophage colony-stimulating factor-induced proliferation and gene expression. Blood 1997; 90: 1768-1776.
141. Lee HH, Dadgostar H, Cheng Q, Shu J, Cheng G. NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signalling in B lymphocytes. Proc Natl Acad Sci USA 1999; 96: 9136-9141.
142. Wang CY, Guttridge DC, Mayo MW, Baldwin AS Jr. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 1999; 19: 5923-5929.
143. Zong WX, Edelstein LC, Chen C, Bash J, Gelinas C. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. Genes Dev 1999; 13: 382-387.
144. Grumont RJ, Rourke IJ, Gerondakis S. Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation-induced apoptosis. Genes Dev 1999; 13: 400-411.
145. Sedlak TW, Oltvai ZN, Yang E, Wang K, Boise LH, Thompson CB, Korsmeyer SJ. Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc Natl Acad Sci USA 1995; 92: 7834-7838.
146. Zhang H, Cowan-Jacob SW, Simonen M, Greenhalf W, Heim J, Meyhack B. Structural basis of BFL-1 for its interaction with BAX and its anti-apoptotic action in mammalian and yeast cells. J Biol Chem 2000; 275: 11092-11099.
147. Duriez PJ, Wong F, Dorovini-Zis K, Shahidi R, Karsan A. Al functions at the mitochondria to delay endothelial apoptosis in response to tumor necrosis factor. J Biol Chem 2000; 275: 18099-18107.
148. Werner AB, de Vries E, Tait SW, Bontjer I, Borst J. Bcl-2 family member Bfl-1/A1 sequesters truncated bid to inhibit is collaboration with pro-apoptotic Bak or Bax. J. Biol Chem 2002; 277: 22781-22788.
149. Apte SS, Mattei MG, Olsen BR. Mapping of the human BAX gene to chromosome 19q13.3-q13.4 and isolation of a novel alternatively spliced transcript, BAX delta. Genomics 1995; 26: 592-594.
150. Cuddeback SM, Yamaguchi H, Komatsu K, Miyashita T, Yamada M, Wu C, Singh S, Wang HG. Molecular cloning and characterization of Bif-1. A novel Src homology 3 domain-containing protein that associates with Bax. J Biol Chem 2001; 276: 20559-20565.
151. Zha H, Aime-Sempe C, Sato T, Reed JC. Proapoptotic protein Bax heterodimerizes with Bcl-2 and homodimerizes with Bax via a novel domain (BH3) distinct from BH1 and BH2. J Biol Chem 1996; 271: 7440-7444.
152. Schmitt E, Paquet C, Beauchemin M, Dever-Bertrand J, Bertrand R. Characterization of Bax-sigma, a cell death-inducing isoform of Bax. Biochem Biophys Res Commun 2000; 270: 868-879.
153. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293-299.
154. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609-619.
155. Wolter KG, Hsu YT, Smith CL, Nechushtan A, XiXG, Youle RJ. Movement of Bax from the cytosol to mitochondria during apoptosis. J Cell Biol 1997; 139: 1281-1292.
156. Nechushtan A, Smith CL, Hsu YT, Youle RJ. Conformation of the Bax C-terminus regulates subcellular location and cell death. EMBO J 1999; 18: 2330-2341.
157. Suzuki M, Youle RJ, Tjandra N. Structure of Bax: coregulation of dimer formation and iritracellular localization. Cell 2000; 103: 645-654.
158. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999; 13: 1899-1911.
159. Antonsson B, Montessuit S, Sanchez B, Martinou JC. Bax is present as a high molecular weight oligomer/complex in the mitochondrial membrane of apoptotic cells. J Biol Chem 2001; 276: 11615-11623.
160. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002; 2: 183-192.
161. Kuwana T, Mackey MR, Perkins G, Ellisman MH, Latterich M, Schneiter R, Green DR, Newmeyer DD. Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell 2002; 111: 331-342.
162. Rostovtseva TK, Antonsson B, Suzuki M, Youle RJ, Colombini M, Bezrukov SM. J Biol Chem 2004; 279: 13575-13583.
163. Marzo I, Brenner C, Zamzami N, Jurgensmeier JM, Susin SA, Vieira HL, Prevost MC, Xie Z, Matsuyama S, Reed JC, Kroemer G. Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science 1998; 281: 2027-2031.
164. Martinou JC, Green DR. Breaking the mitochondrial barrier. Nat Rev Mol Cell Biol 2001; 2: 63-67.
165. Roucou X, Montessuit S, Antonsson B, Martinou JC. Bax oligomerization in mitochondrial membranes requires tBid (caspase-8-cleaved Bid) and a mitochondrial protein. Biochem J 2002; 368: 915-921.
166. Zamzami N, Kroemer G. Apoptosis: mitochondrial membrane permeabilization - the (w)hole story? Curr Biol 2003; 13: R71-R73.
167. Gross A, Jockel J, Wei MC, Korsmeyer SJ. Enforced dimerization of BAX
168. Hsu YT, Youle RJ. Nonionic detergents induce dimerization among members of the Bcl-2 family. J Biol Chem 1997; 272: 13829-13834.
169. Xiang J, Chao DT, Korsmeyer SJ. BAX-induced cell death may not require interleukin 1 beta-converting enzyme-like proteases. Proc Natl Acad Sci USA 1996; 93: 14559-14563.
170. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91: 479-489.
171. Eskes R, Antonsson B, Osen-Sand A, Montessuit S, Richter C, Sadoul R, Mazzei G, Nichols A, Martinou JC. Bax-induced cytochrome C release from mitochondria is independent of the permeability transition pore but highly dependent on Mg2+ ions. J Cell Biol 1998; 143: 217-224.
172. Finucane DM, Bossy-Wetzel E, Waterhouse NJ, Cotter TG, Green DR. Bax-induced caspase activation and apoptosis via cytochrome c release from mitochondria is inhibitable by Bcl-xL. J Biol Chem 1999; 274: 2225-2233.
173. Marzo I, Brenner C, Zamzami N, Jurgensmeier JM, Susin SA, Vieira HL, Prevost MC, Xie Z, Matsuyama S, Reed JC, Kroemer G. Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science 1998; 281: 2027-2031.
174. Bossy-Wetzel E, Newmeyer DD, Green DR. Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochoridrial transmembrane depolarization. EMBO J 1998; 17: 37-49.
175. Goping IS, Gross A, Lavoie JN, Nguyen M, Jemmerson R, Roth K, Korsmeyer SJ, Shore GC. Regulated targeting of BAX to mitochondria. J Cell Biol 1998; 143: 207-215.
176. McCarthy NJ, Whyte MK, Gilbert CS, Evan GI. Inhibition of Ced-3/ICE-related proteases does not prevent cell death induced by oncogenes, DNA damage, or the Bcl-2 homologue Bak. J Cell Biol 1997; 136: 215-227.
177. Lewis S, Bethell SS, Patel S, Martinou JC, Antonsson B. Purification and biochemical properties of soluble recombinant human Bax. Protein Expr Purif 1998; 13: 120-126.
178. Dibbert B, Weber M, Nikolaizik WH, Vogt P, Schoni MH, Blaser K, Simon HU. Cytokine-mediated Bax deficiency and consequent delayed neutrophil apoptosis: a general mechanism to accumulate effector cells in inflammation. Proc Natl Acad Sci USA 1999; 96: 13330-13335.
179. Shinoura N, Yoshida Y, Asai A, Kirino T, Hamada H. Relative level of expression of Bax and Bcl-XT, determines the cellular fate of apoptosis/necrosis induced by the overexpression of Bax. Oncogene 1999; 18: 5703-5713.
180. Meijerink JP, Mensink EJ, Wang K, Sedlak TW, Sloetjes AW, de Witte T, Waksman G, Korsmeyer SJ. Hematopoietic malignancies demonstrate loss-of-fimction mutations of BAX. Blood 1998; 91: 2991-2997.
181. Ulrich E, Kauffmann-Zeh A, Hueber AO, WilliamsonJ, Chittenden T, Ma A, Evan G. Gene structure, cDNA sequence, and expression of murine Bak, a proapoptotic Bcl-2 family member. Genomics 1997; 44: 195-200.
182. HerbergJA, Phillips S, Beck S, Jones T, Sheer D, Wu JJ, Prochazka V, Barr PJ, Kiefer MC, Trowsdale J. Genomic structure and domain organisation of the human Bak gene. Gene 1998; 211: 87-94.
183. Kiefer MC, Brauer MJ, Powers VC, Wu JJ, Umansky SR, Tomei LD, Barr PJ. Modulation of apoptosis by the widely distributed Bcl-2 homologue Bak. Nature 1995; 374: 736-739.
184. Pearson AS, Spitz FR, Swisher SG, Kataoka M, Sarkiss MG, Meyn RE, McDonnell TJ, Cristiano RJ, Roth JA. Up-regulation of the proapoptotic mediators Bax and Bak after adenovirus-mediated p53 gene transfer in lung cancer cells. Clin Cancer Res 2000; 6: 887-890.
185. Leu JI, Dumont P, Hafey M, Murphy ME, George DL. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol 2004; 6: 443-450.
186. Pammer J, Weninger W, Ban J, Wojta J, Tschachler E. The cell death regulatory protein bak is expressed in endothelial cells in inflamed tissues and Is induced by IFN-gamma in vitro. Biochem Biophys Res Commun 1999; 264: 139-143.
187. Sattler M, Liang H, Nettesheim D, Meadows RP, Harlan JE, Eberstadt M, Yoon HS, Shuker SB, Chang BS, Minn AJ, Thompson CB, Fesik SW. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 1997; 275: 983-986.
188. Wei MC, Lindsten T, Mootha VK, Weiler S, Gross A, Ashiya M, Thompson CB, Korsmeyer SJ. tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev 2000; 14: 2060-2071.
189. Korsmeyer SJ, Wei MC, Saito M, Weiler S, Oh KJ, Schlesinger PH. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ 2000; 7: 1166-1173.
190. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB, Korsmeyer SJ. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001; 292: 727-730.
191. Sun YF, Yu LY, Saarma M, Timmusk T, Arumae U. Neuron-specific Bcl-2 homology 3 domain-only splice variant of Bak is anti-apoptotic in neurons, but pro-apoptotic in non-neuronal cells. J Biol Chem 2001; 276: 16240-16247.
192. Hsu SY, Kaipia A, McGee E, Lomeli M, Hsueh AJ. Bokis a pro-apoptotic Bcl-2 protein with restricted expression in reproductive tissues and heterodimerizes with selective anti-apoptotic Bcl-2 family members. Proc Natl Acad Sci USA 1997; 94: 12401-12406.
193. Inohara N, Ekhterae D, Garcia I, Carrio R, Merino J, Merry A, Chen S, Nunez G. Mtd, a novel Bcl-2 family member activates apoptosis in the absence of heterodimerization with Bcl-2 and Bcl-XL. J Biol Chem 1998; 273: 8705-8710.
194. Yang T, Kozopas KM, Craig RW. The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2. J Cell Biol 1995; 128: 1173-1184.
195. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, Tokino T, Taniguchi T, Tanaka N. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000; 288: 1053-1058.
196. Zhang H, Huang Q, Ke N, Matsuyama S, Hammock B, Godzik A, Reed JC. Drosophila proapoptotic Bcl-2/Bax homologue reveals evolutionary conservation of cell death mechanisms. J Biol Chem 2000; 275: 27303-27306.
197. Hsu SY, Hsueh AJ. A splicing variant of the Bcl-2 member Bok with a truncated BH3 domain induces apoptosis but does not dimerize with antiapoptotic Bcl-2 proteins in vitro. J Biol Chem 1998; 273: 30139-30146.
198. Cai Z, Capoulade C, Moyret-Lalle C, Amor-Gueret M, Feunteun J, Larsen AK, Paillerets BB, Chouaib S. Resistance of MCF7 human breast carcinoma cells to TNF-induced cell death is associated with loss of p53 function. Oncogene 1997; 15: 2817-2826.
199. Yakovlev AG, Di Giovanni S, Wang G, Liu W, Stoica B, Faden AI. BOK and NOXA are essential mediators of p53-dependent apoptosis. J Biol Chem 2004; 279: 28367-28374.
200. Brown CY, Bowers SJ, Loring G, Heberden C, Lee RM, Neiman PE. Role of Mtd/Bok in normal and neoplastic B-cell development in the bursa of Fabricius. Dev Comp Immunol 2004; 28: 619-634.
201. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 1995; 80: 285-291.
202. Kaipia A, Hsu SY, Hsueh AJ. Expression and function of a proapoptotic Bcl-2 family member Bcl-XL/Bcl-2-associated death promoter (BAD) in rat ovary. Endocrinology 1997; 138: 5497-5504.
203. Tan Y, Demeter MR, Ruan H, Comb MJ. BAD Ser-155 phosphorylation regulates BAD/Bcl-XL interaction and cell survival. J Biol Chem 2000; 275: 25865-25869.
204. Zhou XM, Liu Y, Payne G, Lutz RJ, Chittenden T. Growth factors inactivate the cell death promoter BAD by phosphorylation of its BH3 domain on Ser155. J Biol Chem 2000; 275: 25046-25051.
205. Datta SR, Katsov A, Hu L, Petros A, Fesik SW, Yaffe MB, Greenberg ME. 14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation. Mol Cell 2000; 6: 41-51.
206. Lizcano JM, Morrice N, Cohen P. Regulation of BAD by cAMP-dependent protein kinase is mediated via phosphorylation of a novel site, Ser155. Biochem J 2000; 349: 547-557.
207. Virdee K, Parone PA, Tolkovsky AM. Phosphorylation of the pro-apoptotic protein BAD on serine 155, a novel site, contributes to cell survival. Curr Biol 2000; 10: 1151-1154.
208. Dramsi S, Scheid MP, Maiti A, Hojabrpour P, Chen X, Schubert K, Goodlett DR, Aebersold R, Duronio V. Identification of a novel phosphorylation site, Ser-170, as a regulator of bad proapoptotic activity. J Biol Chem 2002; 277: 6399-6405.
209. Zhang B, Zhang Y, Shacter E. Rac1 inhibits apoptosis in human lymphoma cells by stimulating Bad phosphorylation on Ser-75. Mol Cell Biol 2004; 24: 6205-6214.
210. Won J, Kim DY, La M, Kim D, Meadows GG, Joe CO. Cleavage of 14-3-3 protein by caspase-3 facilitates bad interaction with Bcl-x(L) during apoptosis. J Biol Chem 2003; 278: 19347-19351.
211. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91: 231-241.
212. Del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez. G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997; 278: 687-689.
213. Datta SR, Ranger AM, Lin MZ, Sturgill JF, Ma YC, Cowan CW, Dikkes P, Korsmeyer SJ, Greenberg ME. Survival factor-mediated BAD phosphorylation raises the mitochondrial threshold for apoptosis. Dev Cell 2002; 3: 631-643.
214. Eisenmann KM, VanBrocklin MW, Staffend NA, Kitchen SM, Koo HM. Mitogen-activated protein kinase pathway-dependent tumor-specific survival signalling in melanoma cells through inactivation of the proapoptotic protein Bad. Cancer Res 2003; 63: 8330-8337.
215. Li WQ, Jiang Q, Khaled AR, Keller JR, Durum SK. Interleukin-7 inactivates the pro-apoptotic protein Bad promoting T cell survival. J Biol Chem 2004; 279: 29160-29166.
216. Fang X, Yu S, Eder A, Mao M, Bast RC Jr, Boyd D, Mills GB. Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway. Oncogene 1999; 18: 6635-6640.
217. Zhu Y, Yang GY, Ahlemeyer B, Pang L, Che XM, Culmsee C, Klumpp S, Krieglstein J. Transforming growth factor-beta 1 increases bad phosphorylation and protects neurons against damage. J Neurosci 2002; 22: 3898-3909.
218. Valks DM, Cook SA, Pham FH, Morrison PR, Clerk A, Sugden PH. Phenylephrine promotes phosphorylation of Bad in cardiac myocytes through the extracellular signal-regulated kinases 1/2 and protein kinase A. J Mol Cell Cardiol 2002; 34: 749-763.
219. Cotteret S, Jaffer ZM, Beeser A, ChernoffJ. p21-Activated kinase 5 (Pak5) localises to mitochondria and inhibits apoptosis by phosphorylating BAD. Mol Cell Biol 2003; 23: 5526-5539.
220. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999; 13: 2905-2927.
221. Schurmann A, Mooney AF, Sanders LC, Sells MA, Wang HG, Reed JC, Bokoch GM. p21-activated kinase 1 phosphorylates the death agonist Bad and protects cells from apoptosis. Mol Cell Biol 2000; 20: 453-461.
222. Jakobi R, Moertl E, Koeppel MA. p21-activated protein kinase gamma-PAK suppresses programmed cell death of BALB3T3 fibroblasts. J Biol Chem 2001; 276: 16624-16634.
223. Gnesutta N, Qu J, Minden A. The serine/threonine kinase PAK4 prevents caspase activation and protects cells from apoptosis. J Biol Chem 2001; 276: 14414-14419.
224. Cotteret S, Jaffer ZM, Beeser A, Chernoff J. p21-activated kinase 5 (Pak5) localises to mitochondria and inhibits apoptosis by phosphorylating BAD. Mol Cell Biol 2003; 23: 5526-5539.
225. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91: 231-241.
226. Blume-Jensen P, Janknecht R, Hunter T. The kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136. Curr Biol 1998; 8: 779-782.
227. Harada H, Becknell B, Wilm M, Mann M, Huang LJ, Taylor SS, Scott JD, Korsmeyer SJ. Phosphorylation and inactivation of BAD by mitochondria-anchored protein kinase A. Mol Cell 1999; 3: 413-422.
228. Yan B, Zemskova M, Holder S, Chin V, Kraft A, Koskinen PJ, Lilly M. The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. J Biol Chem 2003; 278: 45358-45367.
229. Taghiyev AF, Guseva NV, Harada H, Knudson CM, Rokhlin OW, Cohen MB. Overexpression of BAD potentiates sensitivity to tumor necrosis factor-related apoptosis-inducing ligand treatment in the prostatic carcinoma cell line LNCaP. Mol Cancer Res 2003; 1: 500-507.
230. Seo SY, Chen YB, Ivanovska I, Ranger AM, Hong SJ, Dawson VL, Korsmeyer SJ, Bellows DS, Fannjiang Y, Hardwick JM. BAD is a pro-survival factor prior to activation of its pro-apoptotic function. J Biol Chem 2004; 279: 42240-42249.
231. Wang K, Yin XM, Chao DT, Milliman CL, Korsmeyer SJ. BID: a novel BH3 domain-only death agonist. Genes Dev 1996; 10: 2859-2869.
232. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998; 94: 491-501.
233. Desagher S, Osen-Sand A, Nichols A, Eskes R, Montessuit S, Lauper S, Maundrell K, Antonsson B, Martinou JC. Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J Cell Biol 1999; 144: 891-901.
234. Schendel SL, Azimov R, Pawlowski K, Godzik A, Kagan BL, Reed JC. Ion channel activity of the BH3 only Bcl-2 family member, BID. J Biol Chem 1999; 274: 21932-21936.
235. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998; 94: 481-490.
236. Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 1996; 86: 147-157.
237. Kroemer G, Dallaporta B, Resche-Rigon M. The mitochondrial death/life regulator in apoptosis and necrosis. Annu Rev Physiol 1998; 60: 619-642.
238. Renshaw SA, Dempsey CE, Barnes FA, Bagstaff SM, Dower SK, Bingle CD, Whyte MK. Three novel Bid proteins generated by alternative splicing of the human Bid gene. J Biol Chem 2004; 279: 2846-2855.
239. Muravenko OV, Kashuba VI, Kutsenko AS, Gizatullin RZ, Protopopov AI, Kvasha SM, Al-Amin AN, Zelenin AV, Zabarovsky ER. Human HRK gene maps to position 12q13.1. Chromosome Res 2000; 8: 656.
240. Inohara N, Ding L, Chen S, Nunez G. harakiri, a novel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival-promoting proteins Bcl-2 and Bcl-X(L). EMBO J 1997; 16: 1686-1694.
241. Imaizumi K, Tsuda M, Imai Y, Wanaka A, Takagi T, Tohyama M. Molecular cloning of a novel polypeptide, DP5, induced during programmed neuronal death. J Biol Chem 1997; 272: 18842-18848.
242. Sanz C, Benito A, Inohara N, Ekhterae D, Nunez G, Fernandez-Luna JL. Specific and rapid induction of the proapoptotic protein Hrk after growth factor withdrawal in hematopoietic progenitor cells. Blood 2000; 95: 2742-2747.
243. Imaizumi K, Morihara T, Mori Y, Katayama T, Tsuda M, Furuyama T, Wanaka A, Takeda M, Tohyama M. The cell death-promoting gene DP5, which interacts with the BCL2 family, is induced during neuronal apoptosis following exposure to amyloid beta protein. J Biol Chem 1999; 274: 7975-7981.
244. Harris CA, Johnson EM Jr. BH3-only Bcl-2 family members are coordinately regulated by the JNK pathway and require Bax to induce apoptosis in neurons. J Biol Chem 2001; 276: 37754-377560.
245. Shinoe T, Wanaka A, Nikaido T, Kanazawa K, Shimizu J, Imaizumi K, Kanazawa I. Upregulation of the pro-apoptotic BH3-only peptide harakiri in spinal neurons of amyotrophic lateral sclerosis patients. Neurosci Lett 2001; 313: 153-157.
246. Wakabayashi T, Kosaka J, Hommura S. Up-regulation of Hrk, a regulator of cell death, in retinal ganglion cells of axotomized rat retina. Neurosci Lett 2002; 318: 77-80.
247. Sanz C, Benito A, Inohara N, Ekhterae D, Nunez G, Fernandez-LunaJL. Specific and rapid induction of the proapoptotic protein Hrk after growth factor withdrawal in hematopoietic progenitor cells. Blood 2000; 95: 2742-2747.
248. Jurisicora A, Antenos M, Varmuza S, Tilly JL, Casper RF. Expression of apoptosis-related genes during human preimplantation embryo development: potential roles for the Harakiri gene product and Caspase-3 in blastomere fragmentation. Mol Hum Reprod 2003; 9: 133-141.
249. Sanz C, Mellstrom B, Link WA, Naranjo JR, Fernandez-Luna JL. Interleukin 3-dependent activation of DREAM is involved in transcriptional silencing of the apoptotic Hrk gene in hematopoietic progenitor cells. EMBO J 2001; 20: 2286-2292.
250. Sunayama J, Ando Y, Itoh N, Tomiyama A, Sakurada K, Sugiyama A, Kang D, Tashiro F, Gotoh Y, Kuchino Y, Kitanaka C. Physical and functional interaction between BH3-only protein Hrk and mitochondrial pore-forming protein p32. Cell Death Differ 2004; 11: 771-781.
251. Bouillet P, Zhang LC, Huang DC, Webb GC, Bottema CD, Shore P, Eyre HJ, Sutherland GR, Adams JM. Gene structure alternative splicing, and chromosomal localization of pro-apoptotic Bcl-2 relative Bim. Mamm Genome 2001; 12: 163-168.
252. Hsu SY, Lin P, Hsueh AJ. BOD (Bcl-2-related ovarian death gene) is an ovarian BH3 domain-containing proapoptotic Bcl-2 protein capable of dimerization with diverse antiapoptotic Bcl-2 members. Mol Endocrinol 1998; 12: 1432-1440.
253. O'Connor L, Strasser A, O'Reilly LA, Hausmann G, Adams JM, Cory S, Huang DC. Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J 1998; 17: 384-395.
254. O'Reilly LA, Cullen L, Visvader J, Lindeman GJ, Print C, Bath ML, Huang DC, Strasser A. The proapoptotic BH3-only protein bim is expressed in hematopoietic, epithelial, neuronal, and germ cells. Am J Pathol 2000; 157: 449-461.
255. Bouillet P, Metcalf D, Huang DC, Tarlinton DM, Kay TW, Kontgen F, Adams JM, Strasser A. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 1999; 286: 1735-1738.
256. Bouillet P, Huang DC, O'Reilly LA, Puthalakath H, O'Connor L, Cory S, Adams JM, Strasser A. The role of the pro-apoptotic Bcl-2 family member him in physiological cell death. Ann NY Acad Sci 2000; 926: 83-89.
257. Shinjyo T, Kuribara R, Inukai T, Hosoi H, Kinoshita T, Miyajima A, Houghton PJ, Look AT, Ozawa K, Inaba T. Downregulation of Bim, a proapoptotic relative of Bcl-2, is a pivotal step in cytokine-initiated survival signalling in murine hematopoietic progenitors. Mol Cell Biol 2001; 21: 854-864.
258. Whitfield J, Neame SJ, Paquet L, Bernard O, Ham J. Dominant-negative c-Jun promotes neuronal survival by reducing BIM expression and inhibiting mitochondrial cytochrome c release. Neuron 2001; 29: 629-643.
259. Putcha GV, Moulder KL, Golden JP, Bouillet P, Adams JA, Strasser A, Johnson EM. Induction of BIM, a proapoptotic BH3-only BCL-2 family member, is critical for neuronal apoptosis. Neuron 2001; 29: 615-628.
260. Mami U, Miyashita T, Shikama Y, Tadokoro K, Yamada M. Molecular cloning and characterization of six novel isoforms of human Bim, a member of the proapoptotic Bcl-2 family. FEBS Lett 2001; 509: 135-141.
261. Liu JW, Chandra D, Tang SH, Chopra D, Tang DG. Identification and characterization of Bimgamma, a novel proapoptotic BH3-only splice variant of Bim. Cancer Res 2002; 62: 2976-2981.
262. Puthalakath H, Huang DC, O'Reilly LA, King SM, Strasser A. The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Mol Cell 1999; 3: 287-296.
263. Dijkers PF, Medema RH, Lammers JW, Koenderman L, Coffer PJ. Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol 2000; 10: 1201-1204.
264. Putcha GV, Moulder KL, Golden JP, Bouillet P, Adams JA, Strasser A, Johnson EM. Induction of BIM, a proapoptotic BH3-only BCL-2 family member, is critical for neuronal apoptosis. Neuron 2001; 29: 615-628.
265. Strasser A, Puthalakath H, Bouillet P, Huang DC, O'Connor L, O'Reilly LA, Cullen L, Cory S, Adams JM. The role of bim, a proapoptotic BH3-only member of the Bcl-2 family in cell-death control. Ann NY Acad Sci 2000; 917: 541-548.
266. Ley R, Ewings KE, Hadfield K, Howes E, Balmanno K, Cook SJ. Extracellular signal-regulated kinases 1/2 are serum-stimulated "Bim(EL) kinases" that bind to the BH3-only protein Bim(EL) causing its phosphorylation and turnover. J Biol Chem 2004; 279: 8837-8847.
267. Chen D, Zhou Q. Caspase cleavage of BimEL triggers a positive feedback amplification of apoptotic signalling. Proc Natl Acad Sci USA 2004; 101: 1235-1240.
268. Luciano F, Jacquel A, Colosetti P, Herrant M, Cagnol S, Pages G, Auberger P. Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene 2003; 22: 6785-6793.
269. Putcha GV, Le S, Frank S, Besirli CG, Clark K, Chu B, Alix S, Youle RJ, LaMarche A, Maroney AC, Johnson EM Jr. JNK-mediated BIM phosphorylation potentiates BAX-dependent apoptosis. Neuron 2003; 38: 899-914.
270. Hildeman DA, Zhu Y, Mitchell TC, Bouillet P, Strasser A, Kappler J, Marrack P. Activated T cell death in vivo mediated by proapoptotic bcl-2 family member bim. Immunity 2002; 16: 759-767.
271. Puthalakath H, Strasser A. Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ 2002; 9: 505-512.
272. Hildeman DA, Zhu Y, Mitchell TC, Kappler J, Marrack P. Molecular mechanisms of activated T cell death in vivo. Curr Opin Immunol 2002; 14: 354-359.
273. Whitfield J, Neame SJ, Paquet L, Bernard O, Ham J. Dominant-negative c-Jun promotes neuronal survival by reducing BIM expression and inhibiting mitochoridrial cytochrome c release. Neuron 2001; 29: 629-643.
274. Putcha GV, Moulder KL, Golden JP, Bouillet P, Adams JA, Strasser A, Johnson EM. Induction of BIM, a proapoptotic BH3-only BCL-2 family member, is critical for neuronal apoptosis. Neuron 2001; 29: 615-628.
275. Harris CA, Johnson EM Jr. BH3-only Bcl-2 family members are coordinately regulated by the JNK pathway and require Bax to induce apoptosis in neurons. J Biol Chem 2001; 276: 37754-37760.
276. Foncea R, Galvez A, Perez V, Morales MP, Calixto A, Melendez J, Gonzalez-Jara F, Diaz-Araya G, Sapag-Hagar M, Sugden PH, LeRoith D, Lavandero S. Extracellular regulated kinase, but not protein kinase C, is an antiapoptotic signal of insulin-like growth factor-1 on cultured cardiac myocytes. Biochem Biophys Res Commun 2000; 273: 736-744.
277. Reginato MJ, Mills KR, Paulus JK, Lynch DK, Sgroi DC, Debnath J, Muthuswamy SK, Brugge JS. Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis. Nat Cell Biol 2003; 5: 733-740.
278. Weston CR, Balmanno K, Chalmers C, Hadfield K, Molton SA, Ley R, Wagner EF, Cook SJ. Activation of ERK1/2 by deltaRaf-1:ER* represses Bim expression independently of the JNK or PI3K pathways. Oncogene 2003; 22: 1281-1293.
279. Dijkers PF, Birkenkamp KU, Lam EW, Thomas NS, Lammers JW, Koenderman L, Coffer PJ. FKHR-L1 can act as a critical effector of cell death induced by cytokine withdrawal: protein kinase B-enhanced cell survival through maintenance of mitochondrial integrity. J Cell Biol 2002; 156: 531-542.
280. Stahl M, Dijkers PF, Kops GJ, Lens SM, Coffer PJ, Burgering BM, Medema RH. The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2. J Immunol 2002; 168: 5024-5031.
281. Sandalova E, Wei CH, Masucci MG, Levitsky V. Regulation of expression of Bcl-2 protein family member Bim by T cell receptor triggering. Proc Natl Acad Sci USA 2004; 101: 3011-3016.
282. Boyd JM, Malstrom S, Subramanian T, Venkatesh LK, Schaeper U, Elangovan B, D'Sa-Eipper C, Chinnadurai G. Adenovirus E1B 19 kDa and Bcl-2 proteins interact with a common set of cellular-proteins. Cell 1994; 79: 341-351.
283. Yasuda M, D'Sa-Eipper C, Gong XL, Chinnadurai G. Regulation of apoptosis by a Caenorhabditis elegans BNIP3 homolog. Oncogene 1998; 17: 2525-2530.
284. Cizeau J, Ray R, Chen G, Gietz RD, Greenberg AH. The C. elegans orthologue ceBNIP3 interacts with CED-9 and CED-3 but kills through a BH3- and caspase-independent mechanism. Oncogene 2000; 19: 5453-5463.
285. Zhang H, Heim J, Meyhack B. Novel BNIP1 variants and their interaction with BCL2 family members. FEBS Lett 1999; 448: 23-27.
286. Yasuda M, Chinnadurai G. Functional identification of the apoptosis effector BH3 domain in cellular protein BNIP1. Oncogene 2000; 19: 2363-2367.
287. Garnier M, Di Lorenzo D, Albertini A, Maggi A. Identification of estrogen-responsive genes in neuroblastoma SK-ER3 cells. J Neurosci 1997; 17: 4591-4599.
288. Zhou YT, Soh UJ, Shang X, Guy GR, Low BC.The BNIP-2 and Cdc42GAP homology/Sec14p-like domain of BNIP-Salpha is a novel apoptosis-inducing sequence. J Biol Chem 2002; 277: 7483-7492.
289. Zhang HM, Yanagawa B, Cheung P, Luo H, Yuan J, Chau D, Wang A, Bohunek L, Wilson JE, McManus BM, Yang D. Nip21 gene expression reduces coxsackievirus B3 replication by promoting apoptotic cell death via a mitochondria-dependent pathway. Circ Res 2002; 90: 1251-1258.
290. Chen G, Cizeau J, Vande Velde C, Park JH, Bozek G, Bolton J, Shi L, Dubik D, Greenberg A. Nix and Nip3 form a subfamily of pro-apoptotic mitochondrial proteins. J Biol Chem 1999; 274: 7-10.
291. Matsushima M, Fujiwara T, Takahashi E, Minaguchi T, Eguchi Y, Tsujimoto Y, Suzumori K, Nakamura Y. Isolation, mapping, and functional analysis of a novel human cDNA (BNIP3L) encoding a protein homologous to human NIP3.Genes Chromosomes Cancer 1998; 21: 230-235.
292. Shen L, Hu J, Lu H, Wu M, Qin W, Wan D, Li YY, Gu J. The apoptosis-associated protein BNIPL interacts with the two cell proliferation-related proteins, MIF and GFER. FEBS Lett 2003; 540: 86-90.
293. Qin W, Hu J, Guo M, Xu J, Li J, Yao G, Zhou X, Jiang H, Zhang P, Shen L, Wan D, Gu J. BNIPL-2, a novel homologue of BNIP-2, interacts with Bcl-2 and Cdc42GAP in apoptosis. Biochem Biophys Res Commun 2003; 308: 379-385.
294. Farooq M, Kim Y, Im S, Chung E, Hwang S, Sohn M, Kim M, Kim J. Cloning of BNIP3h, a member of proapoptotic BNIP3 family genes. Exp Mol Med 2001; 33: 169-173.
295. Yasuda M, Theodorakis P, Subramanian T, Chinnadurai G. Adenovirus E1B-19K/BCL-2 interacting protein BNIP3 contains a BH3 domain and a mitochondrial targeting sequence. J Biol Chem 1998; 273: 12415-12421.
296. Chen G, Ray R, Dubik D, Shi L, Cizeau J, Bleackley RC, Saxena S, Gietz RD, Greenberg AH. The E1B 19K/Bcl-2-binding protein Nip3 is a dimeric mitochondrial protein that activates apoptosis. J Exp Med 1997; 186: 1975-1983.
297. Vande Velde C, Cizeau J, Dubik D, Alimonti J, Brown T, Israels S, Hakem R, Greenberg AH. BNIP3 and genetic control of necrosis-like cell death through the mitochondrial permeability transition pore. Mol Cell Biol 2000; 20: 5454-5468.
298. Verma S, Budarf ML, Emanuel BS, Chinnadurai G. Structural analysis of the human pro-apoptotic gene Bik: chromosomal localization, genomic organization and localization of promoter sequences. Gene 2000; 254: 157-162.
299. Boyd JM, Gallo GJ, Elangovan B, Houghton AB, Malstrom S, Avery BJ, Ebb RG, Subramanian T, Chittenden T, Lutz RJ, et al. Bik, a novel death-inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins. Oncogene 1995; 11: 1921-1928.
300. Daniel PT, Pun KT, Ritschel S, Sturm I, Holler J, Dorken B, Brown R. Expression of the death gene Bik/Nbk promotes sensitivity to drug-induced apoptosis in corticosteroid-resistant T-cell lymphoma and prevents tumor growth in severe combined immunodeficient mice. Blood 1999; 94: 1100-1107.
301. Mathai JP, Germain M, Marcellus RC, Shore GC. Induction and endoplasmic reticulum location of BIK/NBK in response to apoptotic signalling by E1A and p53. Oncogene 2002; 21: 2534-2544.
302. Boyd JM, Malstrom S, Subramanian T, Venkatesh LK, Schaeper U, Elangovan B, D'Sa-Eipper C, Chinnadurai G. Adenovirus E1B 19 kDa and Bcl-2 proteins interact with a common set of cellular proteins. Cell 1994; 79: 341-351.
303. Han J, Sabbatini P, White E. Induction of apoptosis by human Nbk/Bik, a BH3-containing protein that interacts with E1B 19K. Mol Cell Biol 1996; 16: 5857-5864.
304. Elangovan B, Chinnadurai G. Functional dissection of the pro-apoptotic protein Bik. Heterodimerization with anti-apoptosis proteins is insufficient for induction of cell death. J Biol Chem 1997; 272: 24494-24498.
305. Verma S, Zhao LJ, Chinnadurai G. Phosphorylation of the pro-apoptotic protein BIK: mapping of phosphorylation sites and effect on apoptosis. J Biol Chem 2001; 276: 4671-4676.
306. Orth K, Dixit VM. Bik and Bak induce apoptosis downstream of CrmA but upstream of inhibitor of apoptosis. J Biol Chem 1997; 272: 8841-8844.
307. Jiang A, Clark EA. Involvement of bik, a proapoptotic member of the bcl-2 family, in surface igm-mediated b cell apoptosis. J Immunol 2001; 166: 6025-6033.
308. Marshansky V, Wang X, Bertrand R, Luo H, Duguid W, Chinnadurai G, Kanaan N, Vu MD, Wu J. Proteasomes modulate balance among proapoptotic and antiapoptotic Bcl-2 family members and compromise functioning of the electron transport chain in leukemic cells. J Immunol 2001; 166: 3130-3142.
309. Hegde R, Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Alnemri ES. Blk, a BH3-containing mouse protein that interacts with Bcl-2 and Bcl-xL, is a potent death agonist. J Biol Chem 1998; 273: 7783-7786.
310. Paquet C, Schmitt E, Beauchemin M, Bertrand R. Activation of multidomain and BH3-only proapoptotic Bcl-2 family members in p53-defective cells. Apoptosis 2004; 9: 815-831.
311. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, Tokino T, Taniguchi T, Tanaka N. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000; 288: 1053-1058.
312. Eferl R, Ricci R Kenner L, Zenz R, David JP, Rath M, Wagner EF. Liver tumor development. c-Jun antagonizes the proapoptotic acthity of p53. Cell 2003; 112: 181-192.
313. Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F, Jacks T. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002; 416: 560-564.
314. Seo YW, Shin JN, Ko KH, Cha JH, Park JY, Lee BR, Yun CW, Kim YM, Seol DW, Kim DW, Yin XM, Kim TH. The molecular mechanism of Noxa-induced mitochondrial dysfunction in p53-mediated cell death. J Biol Chem 2003; 278: 48292-48299.
315. Kim JY, Ahn HJ, Ryu JH, Suk K, Park JH. BH3-only protein Noxa is a mediator of hypoxic cell death induced by hypoxia-inducible factor 1alpha. J Exp Med 2004; 199: 113-124.
316. Puthalakath H, Villunger A, O'Reilly LA, Beaumont JG, Coultas L, Cheney RE, Huang DC, Strasser A. Bmf: a proapoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis. Science 2001; 293: 1829-1832.
317. Day CL, Puthalakath H, Skea G, Strasser A, Barsukov I, Lian LY Huang DC, Hinds MG. Localization of dynein light chains 1 and 2 and their pro-apoptotic ligands. Biochem J 2004; 377: 597-605.
318. Puthalakath H, Huang DC, O'Reilly LA, King SM, Strasser A. The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Mol Cell 1999; 3: 287-296.
319. Lei K, Davis RJ. JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. Proc Natl Acad Sci USA 2003; 100: 2432-2437.
320. Morales AA, Olsson A, Celsing F, Osterborg A, Jondal M, Osorio LM. Expression and transcrip-tional regulation of functionally distinct Bmf isoforms in B-chronic lymphocytic leukemia cells. Leukemia 2004; 18: 41-47.
321. Miura I, Siegfried JM, Resau J, Keller SM, Zhou JY, Testa JR. Chromosome alterations in 21 non-small cell lung carcinomas. Genes Chromosomes Cancer 1990; 2: 328-338.
322. Nawroz H, van der Riet P, Hruban RH, Koch W, Ruppert JM, Sidransky D. Allelotype of head and neck squamous cell carcinoma. Cancer Res 1994; 54: 1152-1155.
323. Johns MM 3rd, Westra WH, Califano JA, Eisele D, Koch WM, Sidransky D. Allelotype of salivary gland tumors. Cancer Res 1996; 56: 1151-1154.
324. Mutirangura A, Tanunyutthawongese C, Pornthanakasem W, Kerekhanjanarong V, Sriuranpong V, Yenrudi S, Supiyaphun P, Voravud N. Genomic alterations in nasopharyngeal carcinoma: loss of heterozygosity and Epstein-Barr virus infection. Br J Cancer 1997; 76: 770-776.
325. Han J, Remington C, Houghton AB, Gu Z, Zambetti GP, Lutz RJ, Zhu L, Chittenden T. Expression of bbc3, a pro-apoptotic BH3-only gene, is regulated by diverse cell death and survival signals. Proc Natl Acad Sci USA 2001; 98: 11318-11323.
326. Sanchez-Cespedes M, Ahrendt SA, Piantadosi S, Rosell R, Monzo M, Wu L, Westra WH, Yang SC, Jen J, Sidransky D. Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. Cancer Res 2001; 61: 1309-1313.
327. Hoque MO, Begum S, Sommer M, Lee T, Trink B, Ratovitski E, Sidransky D. PUMA in head and neck cancer. Cancer Lett 2003; 199: 75-81.
328. Yu J, Zhang L, Hwang PM. Kinzler KW, Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 2001; 7: 673-682.
329. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001; 7: 683-694.
330. Villunger A, Michalak EM, Coultas L, Mullauer F, Bock G, Ausserlechner MJ, Adams JM, Strasser A. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 2003; 302: 1036-1038.
331. Jeffers JR, Parganas E, Lee Y, Yang C, Wang J, Brennan J, MacLean KH, Han J, Chittenden T, Ihle JN, McKinnon PJ, Cleveland JL, Zambetti GP. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 2003; 4: 321-328.
332. Liu FT, Newland AC, Jia L. Bax conformational change is a crucial step for PUMA-mediated apoptosis in human leukemia. Biochem Biophys Res Commun 2003; 310: 956-962.
333. Nagase T, Seki N, Ishikawa K, Tanaka A, Nomura N. Prediction of the coding sequences of unidentified human genes. V. The coding sequences of 40 new genes (KIAA0161-KIAA0200) deduced by analysis of cDNA clones from human cell line KG-1. DNA Res 1996; 3: 17-24.
334. Kasof GM, Goyal L, White E. Btf, a novel death-promoting transcriptional repressor that interacts with Bcl-2-related proteins. Mol Cell Biol 1999; 19: 4390-4404.
335. Gharavi AG, Yan Y, Scolari F, Schena FP, Frasca GM, Ghiggeri GM, Cooper K, Amoroso A, Viola BF, Battini G, Caridi G, Canova C, Farhi A, Subramanian V, Nelson-Williams C, Woodford S, Julian BA, Wyatt RJ, Lifton RP. IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Nat Genet 2000; 26: 354-357.
336. Haraguchi T, Holaska JM, Yamane M, Koujin T, Hashiguchi N, Mori C, Wilson KL, Hiraoka Y. Emerin binding to Btf, a death-promoting transcriptional repressor, is disrupted by a missense mutation that causes Emery-Dreifuss muscular dystrophy. Eur J Biochem 2004; 271: 1035-1045.
337. Kataoka T, Holler N, Micheau O, Martinon F, Tinel A, Hofmann K, Tschopp J. Bcl-rambo, a novel Bcl-2 homologue that induces apoptosis via its unique C-terminal extension. J Biol Chem 2001; 276: 19548-19554.
338. Yi P, Zhang W, Zhai Z, Miao L, Wang Y, Wu M. Bcl-rambo beta, a special splicing variant with an insertion of an Alu-like cassette, promotes etoposide- and Taxol-induced cell death. FEBS Lett 2003; 534: 61-68.
339. Guo B, Godzik A, Reed JC. Bcl-G, a novel pro-apoptotic member of the Bcl-2 family. J Biol Chem 2001; 276: 2780-2785.
340. Montpetit A, Boily G, Sinnett D. A detailed transcriptional map of the chromosome 12p12 tumour suppressor locus. Eur J Hum Genet 2002; 10: 62-71.
341. Nakamura M, Tanigawa Y. Characterization of ubiquitin-like polypeptide acceptor protein, a novel pro-apoptotic member of the Bcl2 family. Eur J Biochem 2003; 270: 4052-4058.
342. Tan KO, Tan KM, Chan SL, Yee KS, Bevort M, Ang KC, Yu VC. MAP-1, a novel proapoptotic protein containing a BH3-like motif that associates with Bax through its Bcl-2 homology domains. J Biol Chem 2001; 276: 2802-2807.
343. Aouacheria A, Arnaud E, Venet S, Lalle P, Gouy M, Rigal D, Gillet G. Nrh, a human homologue of Nr-13 associates with Bcl-Xs and is an inhibitor of apoptosis. Oncogene 2001; 20: 5846-5855.
344. Ke N, Godzik A, Reed JC. Bcl-B, a novel Bcl-2 family member that differentially binds and regulates Bax and Bak. J Biol Chem 2001; 276: 12481-12484.
345. Zhai D, Ke N, Zhang H, Ladror U, Joseph M, Eichinger A, Godzik A, Ng SC, Reed JC. Characterization of the anti-apoptotic mechanism of Bcl-B. Biochem J 2003; 376: 229-236.
346. Zhang H, Holzgreve W, De Geyter C. Bcl2-L-10, a novel anti-apoptotic member of the Bcl-2 family, blocks apoptosis in the mitochondria death pathway but not in the death receptor pathway. Hum Mol Genet 2001; 10: 2329-2339.
347. Rogers S, Wells R, Rechsteiner M. Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis. Science 1986; 234: 364.
348. Shibasaki F, Kondo E, Akagi T, McKeon F. Suppression of signalling through transcription factor NF-AT by interactions between calcineurin and BCL-2. Nature 1997; 386: 728-731.
349. Wng HG, Reed JC. BCL-2, RAF-1 and mitochondrial regulation of apoptosis. Biofactors 1998; 8: 13-16.
350. Huang DC, Adams JM, Gory S. The conserved N-terminal BH4 domain of BCL-2 homologues is essential for inhibition of apoptosis and interaction with CED-4. EMBO J 1998; 117: 1029-1103.
351. Scorilas A, Kyriakopoulou L, Yousef GM, Ashworth LK Kwamie A, Diamandis EP. Molecular cloning, physical mapping, and expression analysis of a novel gene, BCL2L12, encoding a proline-rich protein with a highly conserved BH2 domain of the Bcl-2 family. Genomics 2001; 72: 217-221.
352. Hirai H, Varmus HE. Site-directed mutagenesis of the SH2- and SH3-coding domains of c-src produces varied phenotypes, including oncogenic activation of p60c-src. Mol Cell Biol 1990; 10: 1307-1318.
353. Jackson LC, Hotchkiss RN. Cubital tunnel surgery. Complications and treatment of failures. Hand Clin 1996; 12: 449-456.
354. Coultas L, Pellegrini M, Visvader JE, Lindeman GJ, Chen L, Adams JM, Huang DC, Strasser A. Bfk: a novel weakly proapoptotic member of the Bcl-2 protein family with a BH3 and a BH2 region. Cell Death Differ 2003; 10: 185-92.
355. Satou T, Cummings BJ, Cotman CW. Immunoreactivity for Bcl-2 protein within neurons in the Alzheimer's disease brain increases with disease severity. Brain Res 1995; 697: 35-43.
356. Jarskog LF, Gilmore JH. Developmental expression of Bcl-2 protein in human cortex. Brain Res Dev Brain Res 2000; 119: 225-230.
357. Tan J, Town T, Placzek A, Kundtz A, Yu H, Mullan M. Bcl-X(L) inhibits apoptosis and necrosis produced by Alzheimer's beta-amyloidl-40 peptide in PC12 cells. Neurosci Lett 1999; 272: 5-8.
358. Engidawork E, Gulesserian T, Seidl R, Cairns N, Lubec G. Expression of apoptosis related proteins in brains of patients with Alzheimer's disease. Neurosci Lett 2001; 303: 79-82.
359. Hirsch EC, Hunot S, Faucheux B, Agid Y, Mizuno Y, Mochizuki H, Tatton WG, Tatton N, Olanow WC. Dopaminergic neurons degenerate by apoptosis in Parkinson's disease. Mov Disord 1999; 14: 383-385.
360. Mogi M, Harada M, Kondo T, Mizuno Y, Narabayashi H, Riederer P, Nagatsu T. bcl-2 protein is increased in the brain from parkinsonian patients. Neurosci Lett 1996; 215: 137-139.
361. Weiss RA. How does HIV cause AIDS? Science 1993; 260: 1273-1279.
362. Hashimoto F, Oyaizu N, Kalyanaraman VS, Pahwa S. Modulation of Bcl-2 protein by CD4 cross-linking: a possible mechanism for lymphocyte apoptosis in human immunodeficiency virus infection and for rescue of apoptosis by interleukin-2. Blood 1997; 90: 745-753.
363. Regamey N, Harr T, Battegay M, Erb P. Downregulation of Bcl-2, but not of Bax or Bcl-x, is associated with T lymphocyte apoptosis in HIV infection and restored by antiretroviral therapy or by interleukin 2. AIDS Res Hum Retroviruses 1999; 15: 803-810.
364. Re M, Gibellini D, Aschbacher R, Vignoli M, Furlini G, Ramazzotti E, Bertolaso L, La Placa M. High levels of HIV-1 replication show a clear correlation with downmodulation of Bcl-2 protein in peripheral blood lymphocytes of HIV-1-seropositive subjects. J Med Virol 1998; 56: 66-73.
365. French LE, Hahne M, Viard I, Radlgruber G, Zanone R, Becker K, Muller C, Tschopp J. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol 1996; 133: 335-343.
366. Komaki S, Kohno M, Matsuura N, Shimadzu M, Adachi N, Hoshide R, Nishiyama S, Matsuda I. The polymorphic 43Thr bcl-2 protein confers relative resistance to autoimmunity: an analytical evaluation. Hum Genet 1998; 103: 435-440.
367. Guo K, Sear G, Krolikowski D, Pagnoni M, Franks C, Clark K, Yu KT, Jaye M, Ivashchenko Y. Hypoxia induces the expression of the pro-apoptotic gene BNIP3. Cell Death Differ 2001; 8: 367-376.
368. Graham RM, Frazier DP, Thompson JW, Haliko S, Li H, Wasserlauf BJ, Shiga MG, Bishopric NH, Webster KA. A unique pathway of cardiac myocyte death caused by hypoxia-acidosis. J Exp Biol 2004; 207: 3189-3200.
369. Arscott PL, Baker JRJr. Apoptosis and thyroiditis. Clin Immunol Immunopathol 1998; 87: 207-217.
370. Stassi G, Todaro M, Bucchieri F, Stoppacciaro A, Farina F, Zummo G, Testi R, De Maria R. Fas/Fas ligand-driven T cell apoptosis as a consequence of ineffective thyroid immunoprivilege in Hashimoto's thyroiditis. J Immunol 1999; 162: 263-267.
371. Muller-Hocker, J. Expression of bcl-2. Bax and Fas in oxyphil cells of Hashimoto thyroiditis. Virchows Arch 2000; 436: 602-607.
372. Lamhamedi-Cherradi SE, Luan JJ, Eloy L, Fluteau G, Bach JF, Garchon HJ. Resistance of T-cells to apoptosis in autoimmune diabetic (NOD) mice is increased early in life and is associated with dysregulated expression of Bcl-x. Diabetologia 1998; 41: 178-184.
373. Adachi ,M Tefferi A, Greipp PR, Kipps TJ, Tsujimoto Y. Preferential linkage of bcl-2 to immunoglobulin light chain gene in chronic lymphocytic leukemia. J Exp Med 1990; 171: 559-564.
374. Ayhan A, Yasui W, Yokozaki H, Seto M, Ueda R, Tahara E. Loss of heterozygosity at the bcl-2 gene locus and expression of bcl-2 in human gastric and colorectal carcinomas. Jpn J Cancer Res 1994; 85: 584-591.
375. Kondo E, Yoshino T, Yamadori I, Matsuo Y, Kawasaki N, Minowada J, Akagi T. Expression of Bcl-2 protein and Fas antigen in non-Hodgkin's lymphomas. Am J Pathol 1994; 145: 330-337.
376. Binder C, Marx D, Overhoff R, Binder L, Schauer A, Hiddemann W. Bcl-2 protein expression in breast cancer in relation to established prognostic factors and other clinicopathological variables. Ann Oncol 1995; 6: 1005-1010.
377. Ramsay JA, From L, Kahn HJ. bcl-2 protein expression in melanocytic neoplasms of the skin. Mod Pathol 1995; 8: 150-154.
378. Coustan-Smith E, Kitanaka A, Pui CH, McNinch L, Evans WE, Raimondi SC, Behm FG, Arico M, Campana D. Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia. Blood 1996; 87: 1140-1146.
379. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvagcot J, Song K, Kitada S, Reed JC. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996; 148: 1567-1576.
380. Flohil CC, Janssen PA, Bosman FT. Expression of Bcl-2 protein in hyperplastic polyps, adenomas, and carcinomas of the colon. J Pathol 1996; 178: 393-397.
381. Tsuji M, Murakami Y, Kanayama H, Sano T, Kagawa S. Immunohistochemical analysis of Ki-67 antigen and Bcl-2 protein expression in prostate cancer: effect of neoadjuvant hormonal therapy. Br J Urol 1998; 81: 116-121.
382. Malkinson AM. Molecular comparison of human and mouse pulmonary adenocarcinomas. Exp Lung Res 1998; 24: 541-555.
383. Zaja F, Di Loreto C, Amoroso V, Salmaso F, Russo D, Silvestri F, Fanin R, Damiani D, Infanti L, Mariuzzi L, Beltrami CA, Baccarani M. BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine. Leuk Lymphoma 1998; 28: 567-572.
384. LaudanskiJ, Chyczewski L, Niklinska WE, Kretowska M, Furman M, Sawicki B, Niklinski J. Expression of bcl-2 protein in non-small cell lung cancer: correlation with clinicopathology and patient survival. Neoplasma 1999; 46: 25-30.
385. Gobe G, Rubin M, Williams G, Sawczuk I, Buttyan R. Apoptosis and expression of Bcl-2, Bcl-XL, and Bax in renal cell carcinomas. Cancer Invest 2002; 20: 324-332.
386. Martin B, Paesmans M, Berghmans T, Branle F, Ghisdal L, Mascaux C, Meert AP, Steels E, Vallot F, Verdebout JM, Lafitte JJ, Sculier JP. Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. BrJ Cancer 2003; 89: 55-64.
387. Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi M, Angeletti CA, Basolo F, Bevilacqua G. Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer 1995; 71: 1003-1007.
388. Kamesaki S, Kamesaki H, Jorgensen TJ, Tanizawa A, Pommier Y. Cossman J. bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res 1993; 53: 4251-4256.
389. Campos L, Rouault JP, Sabido O, Oriol P, Roubi N, Vasselon C, Archimbaud E, Magaud JP, Guyotat D. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993; 81: 3091-3096.
390. Karakas T, Maurer U, Weidmann E, Miething CC, Hoelzer D, Bergmann L. High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann Oncol 1998; 9: 159-165.
391. Bairey O, Zimra Y, Shaklai M, Okon E, Rabizadeh E. Bcl-2, Bcl-X, Bax, and Bak expression in short-and long-lived patients with diffuse large B-cell lymphomas. Clin Cancer Res 1999; 5: 2860-2866.
392. Tothova E, Fricova M, Stecova N, Kafkova A, Elbertova A. High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Neoplasma 2002; 49: 141-144.
393. Fontana JA, Sun RJ, Rishi AK, Dawson MI, Ordonez JV, Zhang Y, Tschang SH, Bhalla K, Han Z, Wyche J, Poirer G, Sheikh MS, Shroot B, Reichert U. Overexpression of bcl-2 or bcl-XL fails to inhibit apoptosis mediated by a novel retinoid. Oncol Res 1998; 10: 313-324.
394. Murata M, Nagai M, Fujita M, Ohmori M, TakaharaJ. Calphostin C synergistically induces apoptosis with VP-16 in lymphoma cells which express abundant phosphorylated Bcl-2 protein. Cell Mol Life Sci 1997; 53: 737-743.
395. Deng X, Kornblau SM, Ruvolo PP, May WSJr. Regulation of Bcl2 phosphorylation and potential significance for leukemic cell chemoresistance. J Natl Cancer Inst Monogr 2001; 28: 30-37.
396. Riordan FA, Foroni L, Hoffbrand AV, Mehta AB, Wickremasinghe RG. Okadaic acid-induced apoptosis of HL60 leukemia cells is preceded by destabilization of bcl-2 mRNA and downregulation of bcl-2 protein. FEBS Lett 1998; 435: 195-198.
397. Chi KC, Wallis AE, Lee CH, De Menezes DL, Sartor J, Dragowska WH, Mayer LD. Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression. Breast Cancer Res Treat 2000; 63: 199-212.
398. Waters JS, Webb A, Cunningham D, Clarke PA, Raynaud F, di Stefano F, Cotter FE. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2000; 18: 1812-1823.
399. Klasa RJ, Gillum AM, Klem RE, Frankel SR. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev 2002; 12: 193-213.
400. Wang JL, Zhang ZJ, Choksi S, Shan S, Lu Z, Croce CM, Alnemri ES, Korngold R, Huang Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res 2000; 60: 1498-1502.
401. Biroccio A, Leonetti C, Zupi G. The future of antisense therapy: combination with anticancer treatments. Oncogene 2003; 22: 6579-6588.
402. MacCarthy-Morrogh L, Wood L, Brimmell M, Johnson PW, Packham G. Identification of a novel human BCL-X promoter and exon. Oncogene 2000; 19: 5534-5538.
403. Watanabe J, Kushihata F, Honda K, Mominoki K, Matsuda S, Kobayashi N. Bcl-xL Overexpression in human hepatocellular carcinoma. Int J Oncol 2002; 21: 515-519.
404. Gobe G, Rubin M, Williams G, Sawczuk I, Buttyan R. Apoptosis and expression of Bcl-2, Bcl-XL, and Bax in renal cell carcinomas. Cancer Invest 2002; 20: 324-332.
405. Nicot C, Mahieux R, Takemoto S, Franchini G. Bcl-X(L) is up-regulated by HTLV-I and HTLV-II in vitro and in ex vivo ATLL samples. Blood 2000; 96: 275-281.
406. Biroccio A, Benassi B, D'Agnano I, D'Angelo C, Buglioni S, Mottolese M, Ricciotti A, Citro G, Cosimelli M, Ramsay RG, Calabretta B, Zupi G. c-Myb and Bcl-x overexpression predicts poor prognosis in colorectal cancer: clinical and experimental findings. Am J Pathol 2001; 158: 1289-1299.
407. Jaattela M, Benedict M, Tewari M, Shayman JA, Dixit VM. Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells. Oncogene 1995; 10: 2297-2305.
408. Hattori T, Ookawa N, Fujita R, Fukuchi K. Heterodimerization of Bcl-2 and Bcl-X(L) with Bax and Bad in colorectal cancer. Acta Oncol 2000; 39: 495-500.
409. Kitada S, Krajewska M, Zhang X, Scudiero D, Zapata JM, Wang HG, Shabaik A, Tudor G, Krajewski S, Myers TG, Johnson GS, Sausville EA, Reed JC. Expression and location of pro-apoptotic Bcl-2 family protein BAD in normal human tissues and tumor cell lines. Am J Pathol 1998; 152: 51-61.
410. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 1996; 87: 619-628.
411. Ranger AM, Zha J, Harada H, Datta SR, Danial NN, Gilmore AP, Kutok JL, Le Beau MM, Greenberg ME, Korsmeyer SJ. Bad-deficient mice develop diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003; 100: 9324-9329.
412. Zinkel SS, Ong CC, Ferguson DO, Iwasaki H, Akashi K, Bronson RT, Kutok JL, Alt FW, Korsmeyer SJ. Proapoptotic BID is required for myeloid homeostasis and tumor suppression. Genes Dev 2003; 17: 229-239.
413. Wang X, Ryter SW, Dai C, Tang ZL, Watkins SC, Yin XM, Song R, Choi AM. Necrotic cell death in response to oxidant stress involves the activation of the apoptogenic caspase-8/bid pathway. J Biol Chem 2003; 278: 29184-29191.
414. Wagner KW, Engels IH, Deveraux QL. Caspase-2 can function upstream of bid cleavage in the TRAIL apoptosis pathway. J Biol Chem 2004; 279: 35047-35052.
415. Werner AB, Tait SW, de Vries E, Eldering E, Borst J. Requirement for aspartate-cleaved bid in apoptosis signalling by DNA-damaging anti-cancer regimens. J Biol Chem 2004; 279: 28771-28780.
416. Knudson CM, Johnson GM, Lin Y, Korsmeyer SJ. Bax accelerates tumorigenesis in p53-deficient mice. Cancer Res 2001; 61: 659-665.
417. Kaneuchi M, Yamashita T, Shindoh M, Segawa K, Takahashi S, Furuta I, Fujimoto S, Fujinaga K. Induction of apoptosis by the p53-273L (Arg → Leu) mutant in HSC3 cells without transactivation of p21Waf1/Cip1/Sdi1 and bax. Mol Carcinog 1999; 26: 44-52.
418. Sturm I, Papadopoulos S, Hillebrand T, Benter T, Luck HJ, Wolff G, Dorken B, Daniel PT. Impaired BAX protein expression in breast cancer: mutational analysis of the BAX and the p53 gene. Int J Cancer 2000; 87: 517-521.
419. Salah-eldin A, Inoue S, Tsuda M, Matsuura A. Abnormal intracellular localization of Bax with a normal membrane anchor domain in human lung cancer cell lines. Jpn J Cancer Res 2000; 91: 1269-1277.
420. Inoue K, Kohno T, Takakura S, Hayashi Y, Mizoguchi H, Yokota J. Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines. Leuk Res 2000; 24: 255-262.
421. Marone M, Ferrandina G, Macchia G, Mozzetti S, de Pasqua A, Benedetti-Panici P, Mancuso S, Scambia G. Bcl-2, Bax, Bcl-x(L) and Bcl-x(S) expression in neoplastic and normal endometrium. Oncology 2000; 58: 161-168.
422. Gil J, Yamamoto H, Zapata JM, Reed JC, Perucho M. Impairment of the proapoptotic activity of Bax by missense mutations found in gastrointestinal cancers. Cancer Res 1999; 59: 2034-2037.
423. McJilton MA, Van Sikes C, Wescott GG, Wu D, Foreman TL, Gregory CW, Weidner DA, Harris Ford O, Morgan Lasater A, Mohler JL, Terrian DM. Protein kinase Cepsilon interacts with Bax and promotes survival of human prostate cancer cells. Oncogene 2003; 22: 7958-7968.
424. Lu Y, Yagi T. Apoptosis of human tumor cells by chemotherapeutic anthracyclines is enhanced by Bax overexpression. J Radiat Res (Tokyo) 1999; 40: 263-272.
425. Shinoura N, Saito K, Yoshida Y, Hashimoto M, Asai A, Kirino T, Hamada H. Adenovirus-mediated transfer of bax with caspase-8 controlled by myelin basic protein promoter exerts an enhanced cytotoxic effect in gliomas. Cancer Gene Ther 2000; 7: 739-748.
426. Xiang J, Gomez-Navarro J, Arafat W, Liu B, Barker SD, Alrarez RD, Siegal GP, Curiel DT. Proapoptotic treatment with an adenovirus encoding Bax enhances the effect of chemotherapy in ovarian cancer. J Gene Med 2000; 2: 97-106.
427. Li X, Marani M, Yu J, Nan B, Roth JA, Kagawa S, Fang B, Denner L, Marcelli M. Adenovirus-mediated Bax overexpression for the induction of therapeutic apoptosis in prostate cancer. Cancer Res 2001; 61: 186-191.
428. Sawai H, Kawai S, Domae N. Reduced expression of Bax in ceramide-resistant HL-60 subline. Biochem Biophys Res Commun 2004; 319: 46-49.
429. Tong QS, Zheng LD, Wang L, Liu J, Qian W. BAK overexpression mediates p53-independent apoptosis inducing effects on human gastric cancer cells. BMC Cancer 2004; 4: 33.
430. Kondo S, Shinomura Y, Miyazaki Y, Kiyohara T, Tsutsui S, Kitamura S, Nagasawa Y, Nakahara M, Kanayama S, Matsuzawa Y. Mutations of the bak gene in human gastric and colorectal cancers. Cancer Res 2000; 60: 4328-4330.
431. Jackson S, Harwood C, Thomas M, Banks L, Storey A. Role of Bak in UV-induced apoptosis in skin cancer and abrogation by HPV E6 proteins. Genes Dev 2000; 14: 3065-3073.
432. Pataer A, Fang B, Yu R, Kagawa S, Hunt KK, McDonnell TJ, Roth JA, Swisher SG. Adenoviral Bak overexpression mediates caspase-dependent tumor killing. Cancer Res 2000; 60: 788-792.
433. HerbergJA, Phillips S, Beck S, Jones T, Sheer D, Wu JJ, Prochazka V, Barr PJ, Kiefer MC, Trowsdale J. Genomic structure and domain organisation of the human Bak gene. Gene 1998; 211: 87-94.
434. Kersemaekers AM, Kenter GG, Hermans J, Fleuren GJ, van de Vijver MJ. Allelic loss and prognosis in carcinoma of the uterine cervix. Int J Cancer 1998; 79: 411-417.
435. Nair P, Nair KM, Jayaprakash PG, Pillai MR. Decreased programmed cell death in the uterine cervix associated with high risk human papillomavirus infection. Pathol Oncol Res 1999; 5: 95-103.
436. Krajewski S, Krajewska M, Reed JC. Immunohistochemical analysis of in vivo patterns of Bak expression, a proapoptotic member of the Bcl-2 protein family. Cancer Res 1996; 56: 2849-2855.
437. Wani KM, Huilgol NG, Hongyo T, Shah K, Chatterjee N, Nair CK, Nomura T. Genetic alterations in the coding region of the bak gene in uterine cervical carcinoma. Br J Cancer 2003; 88: 1584-1586.
438. Wang SH, Mezosi E, Wolf JM, Cao Z, Utsugi S, Gauger PG, Doherty GM, Baker JR Jr. IFNgamma sensitization to TRAIL-induced apoptosis in human thyroid carcinoma cells by upregulating Bak expression. Oncogene 2004; 23: 928-935.
439. Cartron PF, Juin P, Oliver L, Martin S, Meflah K, Vallette FM. Nonredundant role of Bax and Bak in Bid-mediated apoptosis. Mol Cell Biol 2003; 23: 4701-4712.
440. Wilson JW, Nostro MC, Balzi M, Faraoni P, Cianchi F, Becciolini A, Potten CS. Bcl-w expression in colorectal adenocarcinoma. Br J Cancer 2000; 82: 178-185.
441. Lee HW, Lee SS, Lee SJ, Um HD. Bcl-w is expressed in a majority of infiltrative gastric adenocarcinomas and suppresses the cancer cell death by blocking stress-activated protein kinase/c-Jun NH2-terminal kinase activation. Cancer Res 2003; 63: 1093-1100.
442. Pritchard DM, Print C, O'Reilly L, Adams JM, Potten CS, Hickman JA. Bcl-w is an important determinant of damage-induced apoptosis in epithelia of small and large intestine. Oncogene 2000; 19: 3955-3959.
443. Spets H, Stromberg T, Georgii-Hemming P, SiljasonJ, Nilsson K, Jernberg-Wiklund H. Expression of the bcl-2 family of pro- and anti-apoptotic genes in multiple myeloma and normal plasma cells: regulation during interleukin-6(IL-6)-induced growth and survival. Eur J Haematol 2002; 69: 76-89.
444. Lee SH, Soung YH, Lee JW, Kim HS, Lee JH, Kim HS, Lee JH, Park JY, Cho YG, Kim CJ, Kim SY, Park WS, Kim SH, Lee JY, Yoo NJ. Mutational analysis of Noxa gene in human cancers. APMIS 2003; 111: 599-604.
445. Jansson AK, Emterling AM, Arbman G, Sun XF. Noxa in colorectal cancer: a study on DNA, mRNA and protein expression. Oncogene 2003; 22: 4675-4678.
446. Yu J, Wang Z, Kinzler KW, Vogelstein B, Zhang L. PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci USA 2003; 100: 1931-1936.
447. Jansson A, Arbman G, Sun XF. mRNA and protein expression of PUMA in sporadic colorectal cancer. Oncol Rep 2004; 12: 1245-1249.
448. Sanchez-Carbayo M, Urrutia M, Gonzalez de Buitrago JM, Navajo JA. Evaluation of two new urinary tumor markers: bladder tumor fibronectin and cytokeratin 18 for the diagnosis of bladder cancer. Clin Cancer Res 2000; 6: 3585-3594.
449. Bouillet P, Cory S, Zhang LC, Strasser A, Adams JM. Degenerative disorders caused by Bcl-2 deficiency prevented by loss of its BH3-only antagonist Bim. Dev Cell 2001; 1: 645-653.
450. Egle A, Harris AW, Bouillet P, Cory S. Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc Natl Acad Sci USA 2004; 101: 6164-6169.
451. Jiang Z, Zheng X, Lytle RA, Higashikubo R, Rich KM. Lovastatin-induced up-regulation of the BH3-only protein, Bim, and cell death in glioblastoma cells. J Neurochem 2004; 89: 168-178.
452. Latil A, Bieche I, Chene L, Laurendeau I, Berthon P, Cussenot O, Vidaud M. Gene expression profiling in clinically localised prostate cancer: a four-gene expression model predicts clinical behavior. Clin Cancer Res 2003; 9: 5477-5485.
453. Yasui K, Mihara S, Zhao C, Okamoto H, Saito-Ohara F, Tomida A, Funato T, Yokomizo A, Naito S, Imoto I, Tsuruo T, Inazawa J. Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res 2004; 64: 1403-1410.
454. Kim JK, Kim KD, Lee E, Lim JS, Cho HJ, Yoon HK, Cho MY, Back KE, Park YP, Paik SG, Choe YK, Lee HG. Up-regulation of Bfl-1/A1 via NF-kappaB activation in cisplatin-resistant human bladder cancer cell line. Cancer Lett 2004; 212: 61-70.
455. Tarte K, Jourdan M, Veyrune JL, Berberich I, Fiol G, Redal N, Shaughnessy J Jr, Klein B. The Bcl-2 family member Bfl-1/A1 is strongly repressed in normal and malignant plasma cells but is a potent anti-apoptotic factor for myeloma cells. Br J Haematol 2004; 125: 373-382.
456. Sanz L, Garcia-Marco JA, Casanova B, de La Fuente MT, Garcia-Gila M, Garcia-Pardo A, Silva A. Bcl-2 family gene modulation during spontaneous apoptosis of B-chronic lymphocytic leukemia cells. Biochem Biophys Res Commun 2004; 315: 562-567.
457. D'Souza B, Rowe M, Walls D. The bfl-1 gene is transcriptionally upregulated by the Epstein-Barr virus LMP1, and its expression promotes the survival of a Burkitt's lymphoma cell line. J Virol 2000; 74: 6652-6658.
458. D'Sa-Eipper C, Subramanian T, Chimiadurai G. bfl-1, a bcl-2 homologue, suppresses p53-induced apoptosis and exhibits potent cooperative transforming activity. Cancer Res 1996; 56: 3879-3882.
459. Yoon HS, Hong SH, Kang HJ, Ko BK, Ahn SH, Huh JR. Bfl-1 gene expression in breast cancer: its relationship with other prognostic factors. J Korean Med Sci 2003; 18: 225-230.
460. Talieri M, Diamandis EP, Katsaros N, Gourgiotis D, Scorilas A. Expression of BCL2L12, a new member of apoptosis-related genes, in breast tumors. Thromb Haemost 2003; 89: 1081-1088.
461. Mathioudaki K, Scorilas A, Papadokostopoulou A, Xynopoulos D, Arnogianaki N, Agnanti N, Talieri M. Expression analysis of BCL2L12, a new member of apoptosis-related genes, in colon cancer. Biol Chem 2004; 385: 779-783.
462. Floros KV, Thomadaki H, Lallas G, Katsaros N, Talieri M, Scorilas A. Cisplatin-induced apoptosis in HL-60 human promyelocytic leukemia cells: differential expression of BCL2 and novel apoptosis-related gene BCL2L12. Ann NY Acad Sci 2003; 1010: 153-158.
463. Floros KV, Thomadaki H, Katsaros N, Talieri M, Scorilas A. mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin. Biol Chem 2004; 385: 1099-1103.
464. Castells A, Ino Y, Louis DN, Ramesh V, Gusella JF, Rustgi AK. Mapping of a target region of allelic loss to a 0.5-cM interval on chromosome 22q13 in human colorectal cancer. Gastroenterology 1999; 117: 831-837.
465. Daniel PT, Pun KT, Ritschel S, Sturm I, Holler J, Dorken B, Brown R. Expression of the death gene Bik/Nbk promotes sensitivity to drug-induced apoptosis in corticosteroid-resistant T-cell lymphoma and prevents tumor growth in severe combined immunodeficient mice. Blood 1999; 94: 1100-1107.
466. Zou Y, Peng H, Zhou B, Wen Y, Wang SC, Tsai EM, Hung MC. Systemic tumor suppression by the proapoptotic gene bik. Cancer Res 2002; 62: 8-12.
467. Li YM, Wen Y, Zhou BP, Kuo HP, Ding Q, Hung MC. Enhancement of Bik antitumor effect by Bik mutants. Cancer Res 2003; 63: 7630-7633.
468. Cho-Vega JH, Rassidakis GZ, Admirand JH, Oyarzo M, Ramalingam P, Paraguya A, McDonnell TJ, Amin HM, Medeiros LJ. MCL-1 expression in B-cell non-Hodgkin's lymphomas. Hum Pathol 2004; 35: 1095-1100.
469. Backus HH, van Riel JM, van Groeningen CJ, Vos W, Dukers DF, Bloemena E, Wouters D, Pinedo HM, Peters GJ. Rb, mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer. Ann Oncol 2001; 12: 779-785.
470. Tang L, Tron VA, Reed JC, Mah KJ, Krajewska M, Li G, Zhou X, Ho VC, Trotter MJ. Expression of apoptosis regulators in cutaneous malignant melanoma. Clin Cancer Res 1998; 4: 1865-1871.
471. Shigemasa K, Katoh O, Shiroyama Y, Mihara S, Mukai K, Nagai N, Ohama K. Increased MCL-I expression is associated with poor prognosis in ovarian carcinomas. Jpn J Cancer Res 2002; 93: 542-550.
472. Wakabayashi K, Saito H, Kaneko F, Nakamoto N, Tada S, Hibi T. Gene expression associated with the decrease in malignant phenotype of human liver cancer cells following stimulation with a histone deacetylase inhibitor. Int J Oncol 2005; 26: 233-239.
473. Fong PY, Xue WC, Ngan HY, Chan KY, Khoo US, Tsao SW, Chiu PM, Man LS, Cheung AN. Mcl-1 expression in gestational trophoblastic disease correlates with clinical outcome: a differential expression study. Cancer 2005; 103: 268-276.
474. O'Driscoll L, Cronin D, Kennedy SM, Purcell R, Linehan R, Glynn S, Larkin A, Scanlon K, McDermott EW, Hill AD, O'Higgins NJ, Parkinson M, Clynes M. Expression and prognostic relevance of Mcl-1 in breast cancer. Anticancer Res 2004; 24: 473-482.
475. Spets H, Stromberg T, Georgii-Hemming P, Siljason J, Nilsson K, Jernberg-Wiklund H. Expression of the bcl-2 family of pro- and anti-apoptotic genes in multiple myeloma and normal plasma cells: regulation during interleukin-6(IL-6)-induced growth and survival. Eur J Haematol 2002; 69: 76-89.
476. Ma Y, Cress WD, Haura EB. Flavopiridol-induced apoptosis is mediated through up-regulation of E2F1 and repression of Mcl-1. Mol Cancer Ther 2003; 2: 73-81.
477. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 1992; 44: 1-80.
478. Scorilas A, Yotis J, Gouriotis D, Keramopoulos A, Ampela K, Trangas T, Talieri M. Cathepsin-D and c-erb-B 2 have an additive prognostic value for breast cancer patients. Anticancer Res 1993; 13: 1895-1900.
479. Ardavanis A, Gerakini F, Amanatidou A, Scorilas A, Pateras C, Garoufali A, Pissakas G, Stravolemos K, Apostolikas N, Yiotis I. Relationships between cathepsin-D, pS2 protein and hormonal receptors in breast cancer cytosols: inconsistency with their established prognostic significance. Anticancer Res 1997; 17: 3665-3669.
480. Ardavanis A, Scorilas A, Loukeri A, Gerakini F, Pissakas G, Missitzis I, Apostolikas N, Yiotis I. Cathepsin D may help in discriminating node-negative breast cancer patients at risk for local-regional recurrence. Anticancer Res 1998; 18: 2885-2890.
481. Scorilas A, Yotis J, Pateras C, Trangas T, Talieri M. Predictive value of c-erbB-2 and cathepsin-D for Greek breast cancer patients using univariate and multivariate analysis. Clin Cancer Res 1999; 5: 815-821.
482. Scorilas A, Trangas T, Yotis J, Pateras C, Talieri M. Determination of c-myc amplification and overexpression in breast cancer patients: evaluation of its prognostic value against c-erbB-2, cathepsin-D and clinicopathological characteristics using univariate and multivariate analysis. Br J Cancer 1999; 81: 1385-1391.
483. Lindsten T, Ross AJ, King A, Zong WX, Rathmell JC, Shiels HA, Ulrich E, Waymire KG, Mahar P, Frauwirth K, Chen Y, Wei M, Eng VM, Adelman DM, Simon MC, Ma A, Golden JA, Evan G, Korsmeyer SJ, MacGregor GR, Thompson CB. The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol Cell 2000; 6: 1389-1399.
484. Talieri M, Papadopoulou S, Scorilas A, Xynopoulos D, Arnogianaki N, Plataniotis G, Yotis J, Agnanti N. Cathepsin B and cathepsin D expression in the progression of colorectal adenoma to carcinoma. Cancer Lett 2004; 205: 97-106.